Low Endotoxin Recovery - Detection of Endotoxins in Common Biopharmaceutical Product Formulations by Reich, Johannes
 Low Endotoxin Recovery - Detection of 
Endotoxins in Common Biopharmaceutical 
Product Formulations 
 
 
 
Dissertation 
zur Erlangung des Doktorgrades der Naturwissenschaften 
(Dr. rer. nat.) 
an der Fakultät für Chemie und Pharmazie 
der Universität Regensburg 
 
 
 
vorgelegt von 
Johannes Reich 
aus Regensburg 
2016  
  2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Die Arbeit wurde angeleitet von: Prof. Dr. Hubert Motschmann 
Promotionsgesuch eingereicht am: 05.07.2016 
Promotionskolloquium am: 04.08.2016 
 
 
Prüfungsausschuss:  
Vorsitz: PD Dr. habil. Axel Dürkop 
1. Gutachter: Prof. Dr. Hubert Motschmann 
2. Gutachter: Prof. Dr. Dr. h.c. Ulrich Koszinowski 
3. Prüfer: Prof. Dr. Joachim Wegener 
  
  3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
...no matter how many instances of white swans we may have observed, this does not 
justify the conclusion that all swans are white. 
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II. Zusammenfassung 
Bakterien gehören zu den ersten und ältesten Lebewesen auf der Erde und aufgrund ihrer 
Allgegenwärtigkeit ist der Mensch permanent in direktem Kontakt mit ihnen. In dieser Arbeit wird 
einem Abbauprodukt der Gram-negativen Bakterien, den sogenannten Endotoxinen, spezielle 
Aufmerksamkeit gewidmet. Diese sind der Hauptbestandteil der äußeren Membran von Gram-
negativen Bakterienzellen und werden während des Wachstums oder beim Absterben und der 
Lyse freigesetzt. Endotoxine sind für den Menschen generell nicht gesundheitsschädlich, solange 
sie nicht in den Blutkreislauf eingetragen werden. In diesem Fall können sie jedoch zu 
schwerwiegenden pathogenen Wirkungen führen (z.B. Sepsis). Ein potentielles Risiko der 
Übertragung in den Blutkreislauf ist beispielsweise bei der Injektion von Medikamenten gegeben. 
Um dieses Risiko zu minimieren, sind Hersteller von injizierbaren Medikamenten (Parenteralia) 
verpflichtet, diese streng auf Endotoxin-Kontaminationen zu überprüfen. Hierzu wird 
üblicherweise der „Limulus Amöbozyten Lysat“ Test verwendet. Dieses Testsystem basiert auf 
enzymatischen Reaktionen, die der Blutgerinnungskaskade von Pfeilschwanzkrebsen 
entstammen. Aufgrund der Sensitivität und Anwenderfreundlichkeit stellt diese Methode seit 
Jahren den „Goldstandard“ zur Bestimmung von Endotoxinen dar. Seit neuestem werden jedoch 
Unstimmigkeiten während der Testung von biopharmazeutischen Medikamenten beobachtet. In 
bestimmen Medikamenten konnten die Positivkontrollen nicht innerhalb bestimmter 
Akzeptanzkriterien detektiert werden. Dieser Effekt wird als „Low Endotoxin Recovery (LER)“ 
bezeichnet und führt zu Bedenken auf Anwender- und Behördenseite, ob diese Testmethode 
weiterhin zuverlässig und anwendbar ist.  
In dieser Arbeit wurde die Detektierbarkeit von Endotoxin in biopharmazeutischen 
Formulierungen mittels Limulus-basierten Testmethoden untersucht, um die Ursachen des LER-
Phänomens zu verstehen und die gegenwärtigen Testmethoden zu optimieren. Die präsentierten 
Daten machen deutlich, dass allgemein verwendete Formulierungsbestandteile der 
Medikamente den LER-Effekt verursachen können. Als Hauptursache wurde die simultane 
Anwesenheit von Tensiden und Chelatoren identifiziert. Des Weiteren wird gezeigt, dass LER ein 
zeitabhängiges Phänomen ist und die Reaktionsgeschwindigkeit hauptsächlich von der 
Konzentration des Chelators in der Probenmatrix abhängt. Darüber hinaus wurden verschiedene 
Endotoxine untersucht, die aufgrund ihrer strukturellen Heterogenität unterschiedliche 
Empfindlichkeiten hinsichtlich der Detektierbarkeit aufweisen. Zusammengenommen deuten die 
Daten darauf hin, dass sich das Endotoxin in einem zweistufigen Prozess in Tensidmizellen der 
Probenmatrix einlagert und somit für die Detektion maskiert ist. Mittels dieser Arbeitshypothese 
wurde eine „Toolbox“, mit verschiedenen amphiphilen und chaotropen Reagenzien zur 
Demaskierung des Endotoxins entwickelt. Schließlich wird gezeigt, dass durch eine gezielte 
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Probenvorbereitung der LER-Effekt aufgehoben und das Endotoxin mit herkömmlichen Limulus-
basierten Testmethoden wieder detektiert werden kann. 
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III. Abstract 
Bacteria are one of the first and oldest living organisms on earth and due to their ubiquity, 
humans are permanently in close contact to them. This work focuses on special breakdown 
products of Gram-negative bacteria so-called endotoxins. Endotoxins are the major component 
of the outer membrane of Gram-negative bacteria. They are released during growth or death and 
lysis of the bacterial cell. Endotoxins are usually not hazardous to man, as long as they do not 
enter the circulating blood system. However, if for example endotoxins enter the blood system 
they can lead to severe pathogenic effects like sepsis. One prominent risk is the accidental 
injection of contaminated drug products. In order to reduce this risk, manufacturers of parenteral 
drug products are forced to meticulously control their products before they are released to the 
market. To this end, Limulus Amebocyte Lysate (LAL) assays have been the gold standard for 
detection of bacterial endotoxins since years. These assays are based on enzymatic reactions 
derived from the blood coagulation cascade in horseshoe crabs. Most quality control 
departments in pharmaceutical industry have established such methods to release their drug 
products, because these assays enable fast and sensitive results. However, in the recent past 
inconsistencies during testing of biopharmaceutical drug products have been observed. In certain 
drug products, positive controls of endotoxin were not detectable within given acceptance 
criteria. This effect is called Low Endotoxin Recovery (LER) and users as well as authorities are 
concerned about the reliability of the existing test procedures. 
In this work, the detectability of endotoxin in biopharmaceutical drug product matrices using 
Limulus-based detection systems was analyzed to understand the phenomenon of LER and to 
optimize existing test procedures. The results show that common formulation components of 
biopharmaceutical drug products are capable to induce LER. The minimum prerequisite is the 
simultaneous presence of surfactants and complex forming agents. It is demonstrated that the 
occurrence of LER is time-dependent and that the reaction rate of LER is substantially depending 
on the concentration of the complex forming agents in the sample matrix. Moreover, endotoxins 
from different sources were studied, because their structural heterogeneity may lead to different 
masking susceptibilities. Together, these results indicate that LER is caused by masking of 
endotoxin leading to an alteration of its supramolecular structure, in which endotoxins are 
embedded in surfactant micelles. The further elucidation of a two-step LER reaction mechanism 
served as a basis for the development of a toolbox including amphiphilic and chaotropic reagents, 
which enables the demasking of endotoxin. In conclusion, the dedicated sample treatment using 
such reagents allows the detection of LER-affected endotoxin by Limulus-based detection 
methods.  
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IV. Abbreviations 
API Active Pharmaceutical Ingredient 
Ara4N 4-Amino-4-Deoxyarabinose 
B BSA 
B.cepacia Burkholderia cepacia 
BD BSA + Dodecanol 
BET Bacterial Endotoxin Testing 
BSA Bovine Serum Albumin 
C Calcium Dichloride  
Ci Citrate 
Ca2+ Calcium2+ 
CBSD Calcium dichloride+ BSA+ SDS + Dodecanol 
CMC Critical Micelle Concentration 
CSE Control Standard Endotoxin 
D Dodecanol 
E.cloacae Enterobacter cloacae 
E.coli Escherichia coli 
EDTA Ethylenediaminetetraacetic Acid 
EU Endotoxin Unit 
FDA Food and Drug Administration 
HLB Hydrophilic Hydrophobic Balance 
LAL Limulus Amebocyte Lysate 
LB Lysogeny Broth 
LER Low Endotoxin Recovery 
LPS Lipopolysaccharides 
MAT Monocyte Activation Test 
NOE Naturally Occurring Endotoxin 
OMV Outer Membrane Vesicle 
P.aeruginosa Pseudomonas aeruginosa 
PBS Phosphate-Buffered Saline 
P.mirabilis Proteus mirabilis 
PPC Positive Product Control 
R.pickettii Ralstonia pickettii 
rFC Recombinant Factor C 
rpm Round per Minute 
RPT Rabbit Pyrogen Test 
RSE Reference Standard Endotoxin 
RT Room Temperature 
S SDS 
S.maltophilia Stenotrophomonas maltophilia 
S.marcescens Serratia marcescens 
SDS  Sodium Dodecyl Sulfate 
SDS-PAGE Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
TLR Toll Like Receptor 
TNF Tumor Necrosis Factor 
TRIS 2-Amino-2-(Hydroxymethyl)-1,3-Propanediol  
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1 Fundamentals 
Bacteria are one of the first and oldest living organisms on earth and their diversity is practically 
unlimited. Since modern analytical techniques enable the determination of genetic codes in 
bacteria, they can be categorized by their molecular phylogeny[1]. However, for historical and 
practical reasons bacteria are also classified by structural differences in their cell walls. Based on 
chemical and physical properties of the cell walls, bacteria can be differentiated between Gram-
positive and Gram-negative. This dates back to times in which bacteria were stained (e.g. methyl 
violet) to enhance the visibility of bacteria [2].  
1.1 Endotoxin (LPS) 
Endotoxins are a unique group of molecules, which occur naturally in the cell wall of Gram-
negative bacteria[3]. They are derived for example from various bacteria like Neisseria 
meningitides, Vibrio cholera or Escherichia coli (Figure 1A). If administrated into the blood stream 
of mammalians, bacteria and their toxic breakdown products can cause severe pathogenic effects 
including fever and septic shock[4]. Due to their fever inducing capability, endotoxins are also 
classified as pyrogens.  
 
Figure 1 Gram-negative Bacteria 
A) Scanning electron micrograph of Escherichia coli, grown in culture and adhered to a cover slip.  
(Credit: National Institute of Health, National Institute of Allergy and Infectious Diseases, Image Library). 
B) Schematic representation of the Gram-negative membrane. The outer membrane possesses an 
asymmetric bilayer, in which LPS covers mostly the surface and phospholipids are located in the inner 
leaflet as counter molecules. In addition, a variety of further components like proteins, lipoproteins, 
peptidoglycans are present in the cell envelope of Gram-negative bacteria. (Source: [4]) C) Chemical 
structure of LPS from E. coli O111:B4 LPS. The particular regions of LPS (lipid A, core region and O-
antigen) and the variability of sugar units are indicated. (Source: [5]) 
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The end of the 19th century is of particular importance in the context of endotoxins. Dramatic 
cholera outbreaks threatened large harbor cities including Hamburg, Germany and St. Petersburg, 
Russia and have led to a large number of death. During that time, systematic research began and 
is still ongoing to better understand the hazardous effects of Gram-negative bacteria and 
endotoxins (Figure 2).[6]  
 
Figure 2 The history of endotoxin research 
Research on endotoxins started in the end of 19th century with the description of the deleterious and 
beneficial bioactivities of endotoxins. A further phase comprised efforts undertaking their biochemical 
and immunochemical characterization, while the immunological properties of this molecule were 
mainly defined in the mid-20th century. (Source:[7]) 
Around 1890, Richard Pfeiffer, a co-worker of Robert Koch, stated:  
“In ganz jungen, aerob gezüchteten Choleraculturen ist ein specifischer Giftstoff 
enthalten, welcher ausserordentlich intensive toxische Effecte entfaltet. Dieses 
primäre Choleragift steht in sehr enger Zusammengehörigkeit zu den 
Bacterienleibern und ist vielleicht ein integrirender Bestandtheil derselben. Durch 
Chloroform, Thymol und durch Trocknen können die Choleravibrionen abgetödtet 
werden, ohne dass dieser Giftstoff anscheinend verändert wird.1”[8]  
                                                          
1 In very young aerobically grown cholera cultures, a specific toxic substance is contained which exerts 
extraordinarily intense toxic effects. This primary cholera toxin is closely attached to, and probably an 
integral part of, the bacterial body. By chloroform, thymol, or by drying, the cholera vibrios can be killed 
without any detectable change of the toxin[6]. 
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This was the genesis of the concept of endotoxins. Within the mid of the 20th century, it was 
figured out that endotoxins are located at the surface of Gram-negative bacteria (Figure 1B) and 
are liberated when bacteria multiply, die and lyse[9]. During the development of techniques for 
extracting and preparing endotoxins, lipopolysaccharides (LPS) (Figure 1C) were identified in 
bearing the toxic principle of endotoxin[3]. To this end, the two terms endotoxin and LPS are used 
for the same molecule and thus represent synonyms. However, the term endotoxin reflects its 
biological activity and the term LPS its chemical composition[10]. Moreover, it has been shown 
that LPS are the dominating constitutes of the outer membrane of Gram-negative bacteria and 
LPS play an important role in maintaining the integrity of the membrane architecture and is 
therefore an essential component for bacterial viability. Noteworthy, LPS are accompanied by 
certain proteins and lipids, but LPS covers three-quarters of the bacterial surface and one 
bacterial cell contains approximately 3.5 x 106 LPS molecules.[9]  
1.2 Structure and activity of LPS 
LPS are a broad and complex group of molecules, which possess a common general 
architecture[11]. The molecules can be divided in three parts: O-antigen, core region and lipid A 
(Figure 3)[12]. The latter is based on a phosphorylated diglucosamine which is esterified with fatty 
acids (e.g. caproic acid (C6), lauric acid (C12), myristic acid (C14), palmitic acid (C16), stearic acid 
(C18)) and anchors the molecule in the outer membrane of Gram-negative bacteria and is 
covalently substituted by a saccharide portion. The core region comprises an oligosaccharide 
containing up to fifteen monosaccharides (e.g. diverse heptoses, glucose, galactose and 
mannooctulosonic acid) to which a polysaccharide portion of repeating units, the O-specific chain 
including glucose, galactose, rhamnose and mannose, is linked.[10] Noteworthy, also LPS mutants 
lacking the O-antigen have been isolated. These LPS forms are donated as rough LPS, whereas LPS 
containing O-antigen are called smooth LPS[13]. However, it has been shown that the lipid A part 
represents the “endotoxic principle” of LPS, and in contrast to the role of the polysaccharides 
(core region and O-antigen), alterations of the lipid A moiety were found to influence the 
bioactivity dramatically[14], [15]. Full endotoxic activity is expressed by a molecule containing 
two hexosamine residues, two phosphoryl groups, and six fatty acids including 3-acyloxyacyl 
groups with a defined chain length and at a distinct location[9]. As a consequence, not all LPS are 
toxic, just as not all bacteria are pathogenic[3]. Moreover, due to the hydrophilic (O-antigen and 
core region) and hydrophobic (lipid A) regions, LPS tend to aggregate in aqueous solutions. 
Depending on the molecular structure and environmental conditions diverse supramolecular 
structures either non-lamellar inverted (cubic Q or hexagonal HII) or lamellar can be formed[16]. 
It has been shown in several studies that the aggregation state of LPS affects its biological activity 
as well as its detectability.[14], [16]–[19] 
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Figure 3 Schematic structure of lipopolysaccharides 
With regard to the biological nature, LPS can be divided into three functional subunits: O-antigen, core 
region and lipid A. The latter is the toxic fragment of the molecule. With regard to the chemical 
structure, LPS is an amphiphilic molecule. The fatty acids within the lipid A are hydrophobic and the 
polysaccharides in the core region and O-antigen are hydrophilic. In addition, LPS is electrically charged 
due to substituents (e.g. phosphates) in the core region and on the diglucosamine of lipid A.  
1.3 Clinical relevance of LPS 
Years ago, clinicians have recognized that humans are especially sensitive towards endotoxin. In 
some cases, intravenous infusions containing bacterial contaminants have led to death and 
severe pathogenic response in patients.[20]–[22] Thereby, LPS are able to induce a variety of 
biological effects in-vivo (Figure 4). To fight against pathogenicity, bacteria and its LPS are the 
primary target for interaction with antibacterial drugs and components of the immune system of 
the host.[17] 
 
Figure 4 Schematic representation of the activation mechanisms induced by LPS 
LPS is released from the bacterial outer membrane by the attack of immune components (drugs, 
proteins) or simply by cell division. It may interact with serum and membrane proteins, which 
subsequently leads to an activation of macrophages, which secret mediators such as tumor necrosis 
factors alpha and interleukins. (Source: [17]) 
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In order to understand pathogenicity, an important finding has been the identification of the 
plasma membrane protein Toll-like receptor 4 (TLR4) as the lipid A signaling receptor of animal 
cells. Activation of TLR4 by lipid A triggers the biosynthesis of diverse mediators of inflammation 
including tumor necrosis factor (TNF) or interleukins, ultimately resulting in multiple organ failure, 
septic shock in the case of systemically overproduction.[23] Generally, TLR4 belongs to a family 
of innate immunity receptors (Figure 5) and besides endotoxins, there are also other pathogens, 
which are not limited to Gram-negative bacteria (Lipoteichoic acids, peptidoglycans, proteins etc.) 
and stimulate the innate immune system resulting in pyrogenic reactions. However, endotoxins 
are considered to be an outstanding alarm marker due to their relatively high pyrogenicity. 
Endotoxins are active in the picogram range per kilogram bodyweight. Therefore, a little amount 
of endotoxin can generate a very strong host response.[24] In contrast, peptidoglycans are 50,000 
times less pyrogenic than endotoxins[25].  
 
Figure 5 The Toll-Like-Receptor family 
Toll-like receptors (TLRs) recognize a variety of pathogen-associated molecular patterns. Recognition of 
LPS by TLR4 is aided by accessory proteins (CD14 and MD-2). TLR2 recognizes a broad range of 
structurally unrelated ligands and functions in combination with several (but not all) other TLRs, 
including TLR1 and TLR6. TLR3 is involved in recognition of double-stranded RNA. TLR5 is specific for 
bacterial flagellin, whereas TLR9 is a receptor for unmethylated CpG sequences in DNA. (Source [26]) 
For further comprehension of the pyrogenicity of endotoxins, dose-febrile response curves for 
endotoxins have been studied and it was found that man, cat, horse and rabbits have 
approximately the same threshold to pyrogen simulation by endotoxins. However, larger doses 
are more pyrogenic and more toxic for man than for rabbit, due to much steeper dose-febrile 
response curves for man. Dogs and chimpanzee were notably less susceptible to the pyrogenicity 
of endotoxin than the other species.[27] Moreover, depending on the source of endotoxin 
different thresholds were found to initiate pyrogenicity. For example approximately 0.1 to 1.0 
nanogram per kilogram of bodyweight of endotoxin from E.coli is needed, whereas 50 nanogram 
per kilogram of bodyweight of endotoxin from P.aeruginosa are required for pyrogenic response 
in man[28]. This already gives an indication about the heterogeneity and complexity of 
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endotoxins. In order to enable a comparison of biological activities, endotoxin units (EU) were 
introduced, based on the approximated threshold of pyrogenic activity of E.coli. 1 EU reflects the 
biologic activity of 0.1 nanogram of purified endotoxin from E.coli in man.[24] 
1.4 Need for control of endotoxins and their detection methods 
The occurrence of Gram-negative organisms in virtually every environment on earth makes LPS 
one of the most prevalent complex organic molecules occurring in nature. Gram-negative 
bacteria have been isolated wherever man has gone: in soil, fresh and salt water, frigid oceans 
and hot springs. Minimal growth requirements of Gram-negative bacteria allow their growth in 
the cleanest of water.[24] Therefore, the ubiquity of endotoxins requires routine screening of all 
fluids and medications prepared for parenteral therapy.[27] Although the pyrogenic dose 
response curve in man is much steeper than it is in rabbits, the minimum pyrogenic dose on a 
weight basis in rabbits is in a passable range compared to man[28]. Hence, the Rabbit Pyrogen 
Test (RPT) was introduced as an in-vivo test method for the detection of fever-causing (pyrogenic) 
contaminations in pharmaceutical products, and has already been manifested in various 
pharmacopoeias and guidelines around the world in the 1940th[29]. Over the years, alternative 
in-vitro detection methods were discovered and established. One method of pyrogen detection 
relies on mimicking the human fever reaction, which can be found in the Monocyte Activation 
Test (MAT). It employs the cytokine response of blood monocytes for the detection of 
microbiological contaminants.[30] However, handling of appropriate blood or cell lines for 
running the assay and regulatory issues prolong the universal application of this assay. 
Another and more prominent method was discovered by Bang and Levin in the 1960th. They 
utilized the defense system of an animal with over 450 million years of experience, fighting 
against microbial attacks. It has been demonstrated that bacterial endotoxins rapidly induce 
clotting of the blood of horseshoe crabs[31]. The amebocytes in horseshoe crabs´ hemolymph 
contain a coagulation system, which is activated by minute amounts of endotoxin.[32] The 
principle of this test method is based on an enzymatic reaction cascade. In the presence of LPS, 
an LPS-sensitive serine protease zymogen Factor C, is autocatalytically activated. The active 
Factor C* then activates zymogen Factor B to Factor B*, which subsequently activates proclotting 
enzyme to clotting enzyme. The resulting clotting enzyme converts soluble coagulogen, an 
invertebrate fibrinogen-like substance, to an insoluble coagulin gel. (Figure 6B)[33]. This cascade 
system found in the hemocytes allows for an extremely high sensitivity of the lysate to picogram 
quantities of endotoxins. [34] For production of the so called Limulus Amebocyte Lysate (LAL), 
horseshoe crabs (Figure 6A) are collected when they migrate to shallow coastal waters for 
reproduction. Once collected, the lively crabs are placed in restraining racks. Sterile needles are 
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inserted through the muscular hinge between the cephalothorax and abdominal region[24], [32] 
and up to 150 mL blood of one horseshoe crab can be obtained. If the crabs are handled with 
care, they normally survive this procedure. Depending on country-specific regulations they are 
returned into the ocean or are further processed (e.g. fishing bait). However, after collection the 
blood is centrifuged and the harvested amebocytes are washed. The cells are lysed by addition of 
distilled water and cellular debris is removed by centrifugation. Finally, the lysate is decanted and 
can be used for testing.[35] Comparative studies between LAL tests and the RPT on various 
samples resulted in good agreement and the results achieved by LAL detection methods were 
more sensitive, when samples were properly handled[36], [37].  
 
Figure 6 Horseshoe crabs and their endotoxin specific reaction cascade 
A) Horseshoe crabs at Pickering beach, Delaware, USA. Horseshoe crabs are found along the northeast 
coasts in America and southeast costs in Asia. For reproduction, adult crabs travel during late spring 
and early summer from deep ocean water to coastal water and females deposit eggs on the beaches. 
B) Tentative reaction mechanism for the coagulation cascade of the Limulus amebocyte lysate with 
endotoxin. 
Practical experience and technological progress led from simple test techniques, based on the 
occurrence of gel formation by the reaction of the lysate with endotoxin; to photometric 
techniques, which are based on the change in lysate turbidity during gel formation; and 
chromogenic techniques, which are based on the development of color after cleavage of a 
synthetic peptide-chromogen complex[38]–[40]. Moreover, growing demand and limited 
resources of horseshoe crabs are leading to the use of recombinant sources of Limulus-based 
enzymes. These novel techniques use, recombinantly produced Factor C (rFC), the first enzyme 
of the Limulus coagulation cascade, and a fluorogenic substrate is generating the signal[41], [42]. 
In the present work, mainly recombinant test methods were used. Today, these Limulus-based 
methods including LAL and rFC are recognized as the most sensitive in-vitro assays available for 
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bacterial endotoxin testing (BET). These methods are more economical and require a smaller 
volume of sample for testing than does the RPT and MAT. In addition, a large number of tests can 
be performed by one individual in a single day.  
1.5 Regulatory aspects 
Endotoxin is only a concern for man, when it comes into contact with the circulatory blood 
system. One relevant mechanism for such contact involves medically invasive techniques 
including injection or infusion of parenteral solutions[24]. Therefore, pharmaceutical regulatory 
agencies around the world are asking for BET in parenteral drug products. For example, the 
European Directorate for the Quality of Medicines (EDQM) states that  
“bacterial endotoxins are the most common cause of pyrogenicity in pharmaceutical 
products. Any preparation administered parenterally should be sterile and comply 
with the test for bacterial endotoxins. Substances to be used in parenteral 
preparations must comply with the BET, whatever their origin…”[43] 
In consequence, manufacturers of parenteral drug products are obliged to perform BET of in-
process samples and finished products. Fortunately, the occurrence of contaminations in 
parenteral drugs, devices, infusions and transfusion solutions has been relatively rare since the 
introduction of BET.[24] In order to maintain such a high level, the meticulousness in quality 
control of pharmaceutical products has to retained and continuously improved.  
1.6 Low Endotoxin Recovery 
With regard to certain pharmaceutical drug products some inconsistencies were recognized 
during BET. In 2013, Chen and Vinther from Genentech reported the phenomenon of Low 
Endotoxin Recovery (LER)[44]. During the establishment of diverse test procedures, to simulate 
potential contamination events, known amounts of endotoxin were inadequate detectable. 
Defined amounts of endotoxin were spiked to undiluted drug products and these samples 
containing endotoxins were incubated for a certain period of time. After incubation, the detection 
of spiked endotoxin contents resulted in low endotoxin recovery. Interestingly, this phenomenon 
was mainly observed in biopharmaceutical drug products, in which the Active Pharmaceutical 
Ingredients (API) are proteins like monoclonal antibodies. For stability reasons, such products are 
commonly formulated using excipients like phosphate and citrate buffer systems and 
polysorbates (Table 1). First investigations of affected samples have indicated that excipients of 
the drug products provoke the phenomenon of LER, but non-harmonized test procedures in 
industries leading to confounding results. The observation of this phenomenon is meanwhile 
frequently discussed in many forums, as it may result in an underestimation of hazardous 
endotoxin contents in injectable drug products. The Food and Drug Administration (FDA) pointed 
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out that endotoxin might be present in high amounts in a certain drug product and current assays 
are not detecting it or only detecting “acceptable” levels. Depending on the drug product dose 
and the potential amount of endotoxin contamination a pyrogenic reaction could occur.[45] In 
conclusion, to avoid the underestimation of a potential endotoxin contamination, the driving 
forces of the LER phenomenon have to be understood and current test procedures have to be 
optimized to ensure entire endotoxin detection in biopharmaceutical drug products.  
Table 1 Common formulations of biopharmaceutical drug products 
Monoclonal antibodies are prominent active pharmaceutical ingredients (API) in commercial 
biopharmaceutical drug products. For formulation excipients like phosphate, citrate, sodium chloride 
and polysorbates are used. (Source: http://www.rxlist.com)   
Commercial 
Drug Product: 
Active 
Ingredient: 
Formulation components: 
Actemra ® Tocilizumab Phosphate, Sucrose, Polysorbate 80 
Avastin ® Bevacizumab Phosphate, Trehalose, Polysorbate 20 
Erbitux ® Cetuximab Phosphate, Sodium chloride  
Humira ® Adalimumab Phosphate, Citrate, Mannitol, Sodium chloride, Polysorbate 80 
Lucentis ® Ranibizumab Histidine, Polysorbate 20 
Mabthera ® Rituximab Citrate, Sodium chloride, Polysorbate 80 
Remicade ® Infliximab Phosphate, Sucrose, Polysorbate 80 
Simponi ® Golimumab Histidine, Sorbitol, Polysorbate 80 
Soliris ® Eculizumab Phosphate, Sodium chloride, Polysorbate 80 
Synagis ® Palivizumab Histidine, Glycine, Mannitol 
Tysabri ® Natalizumab Phosphate, Sodium chloride, Polysorbate 80 
Xolair ® Omalizumab Histidine, Sucrose, Polysorbate 20 
 
1.7 Purpose of the study 
Aim of this work is to improve existing test procedures and to detect endotoxin out of samples, 
which are affected by the LER phenomenon. First of all, the phenomenon has to be analyzed 
according to the questioning observations, which were made in pharmaceutical industry. 
Therefore, endotoxin recovery in common formulation components of drug products including 
citrate and phosphate buffer systems as well as surfactants like polysorbates has to be 
investigated. Due to the temporally delayed occurrence of the LER-effect, reaction kinetics has to 
be examined in order to identify the time limiting parameters of LER and to establish a model 
system, which enables the simulation of such kinetics. In addition, as endotoxins represent a 
heterogeneous group of LPS, it has to be examined which influences this variability has on the 
LER-effect and if it is depending on a certain species of endotoxin. Therefore, endotoxins from 
different sources have to be tested with regard to their detectability under LER conditions. After 
analysis of the driving forces, an approach to render the endotoxin detectable has to be figured 
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out. Due to the regulatory scope in pharmaceutical industry, existing test procedures have to be 
maintained, but advanced by sample treatments prior to the actual measurement. Thus, purpose 
of this work is to discover “demasking” agents for sample pre-treatment to detect endotoxin out 
of LER-affected samples using Limulus-based test methods and in turn to reduce the risk of wrong-
negative test results during quality control of drug products in pharmaceutical industries.  
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2 Material and Methods 
2.1 Reagents 
Polysorbate 20, polysorbate 80, octoxynol 9, ethanol, 1-octanol, 1-decanol, 1-dodecanol, 1-
tetradecanol, 1-hexadecanol, 1-octadecanol, sodium chloride, sodium azide, citric acid, trisodium 
citrate, phosphoric acid, sodium dihydrogenphosphate, potasium dihydrogenphosphate,  
disodium hydrogen phosphate-heptahydrate, ethylenediaminetetraacetic acid (EDTA), 2-amino-
2-(hydroxymethyl)-1,3-propanediol (tris), 2-mercaptoethanol, isopropanol, D(+)-glucose, sodium 
chloride, calcium dichloride and magnesium dichloride were obtained from Sigma-Aldrich Chemie 
GmbH, Steinheim, Germany. Ammonium hydroxide, formaldehyde and D(+)-trehalose-dihydrate 
were obtained from AppliChem GmbH, Darmstadt, Germany. Acetic acid, glycerol, periodic acid, 
sodium hydroxide, silver nitrate, sodium dodecylsulfate (SDS) and yeast extract (powdered) were 
obtained from Carl Roth GmbH & Co.KG, Karlsruhe, Germany. Bromophenol blue sodium salt was 
obtained from Merck Chemicals GmbH, Darmstadt, Germany. Bovine Serum Albumin (BSA) and 
20x Tris-tricine/SDS electrophoresis buffer were obtained from Serva Electrophoresis GmbH, 
Heidelberg, Germany. A bovine polyclonal immunoglobulin G (PAK) and a mouse monoclonal 
antibody (MAK33) were obtained from Roche Diagnostics Deutschland GmbH, Mannheim, 
Germany. Tryptone Bacto TM was obtained from Becton Dickinson GmbH, Heidelberg, Germany. 
Prior to the experiments, all relevant materials have been tested on endotoxin contents and were 
proven to contain less than 0.05 EU/mL.   
2.2 Endotoxins and bacteria 
Endotoxin from E.coli O55:B5 (gel-filtrate), P.aeruginosa and S.enterica were obtained from 
Sigma-Aldrich Chemie, Steinheim, Germany. Phenol-extracted clinical isolate endotoxins from 
E.coli, K.pneumonia, M.morganii, Y.enterocolitica, N.meningitis, P.mirabilis and S.marcescens 
were a kind gift from Dr. Andreas Wieser, Universitätsklinik München (LMU), München, Germany. 
Endotoxin from E.coli K12 was obtained from InvivoGen, Toulouse, France. Freeze dried bacteria 
from E.coli O55:B5 (DSM 4779), E.cloacae (DSM 30054) and P.aeruginosa (DSM 500 71) were 
obtained from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, 
Braunschweig, Germany. Freeze dried bacteria from E.coli O113 (Ecor 30) was obtained from 
Escherichia coli Reference Collection, East Lansing, USA. Freeze dried bacteria from B.cepacia 
(2008 B02-12.20.164) and S. maltophilia (DSMZ 50 170) were obtained from Robert Koch-
Institute, Wernigerode, Germany. Bacteria from R.pickettii (isolate) were a kind gift from Hyglos 
GmbH, Bernried, Germany.   
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2.3 Other materials 
20% gradient tris-tricin gel was obtained from Anamed Elektrophorese GmbH, Rodau, Germany. 
0.2 µm Acrodisc 25 mm Syringe Filters were obtained from Pall GmbH, Dreieich, Germany. Kinetic 
chromogenic Limulus Amebocyte Lysate test was obtained from Lonza Inc., Walkersville, USA. 
Depyrogenated water, depyrogenated borosilicate glass tubes and recombinant Factor C tests, 
EndoZyme® and EndoLISA® were obtained from Hyglos GmbH, Bernried, Germany. 
2.4 Preparation of crude endotoxins extracts 
2.4.1 Preparation 1  
For growth of bacteria, 5 mL lysogeny broth (LB) media (10 g/L sodium chloride, 5 g/L yeast extract 
and 10 g/L tryptone) were inoculated with desired bacterial strain, followed by incubation at 37 
°C in a shaking incubator (Platform shaker: Innova 2300, New Brunswick Scientific Co, Enfield, 
USA; Incubator: Wärmeschrank für Plattformschüttler, Mytron Bio- und Solartechnik GmbH, 
Heilbad Heiligenstadt, Germany) overnight. Afterwards 200 µL of the preparatory culture were 
transferred into 500 mL of media (12.8 g/L disodium hydrogenphosphat-heptahydrat, 3 g/L 
potassium dihydrogenphosphat, 0.5 g/L sodium chlorid, 1 g/L ammonium chloride, 0.01 g/L 
calcium dichloride and 0.4 wt % glucose) and incubated for 24 hours at 37 °C. Growth of bacteria 
was tracked by light absorption at 600 nm using a spectro photometer V550 Jasco Germany 
GmbH, Gross-Umstadt, Germany. Bacterial growth was stopped by temperature reduction to 4 
°C, centrifugation at 4500 rpm and sterile filtration (0.2 µm) of the bacterial suspension. For 
conservation 0.05 (v/v) % sodium azide was added. Required endotoxin concentrations for 
endotoxin recovery studies were adjusted by dilution with depyrogenated water.  
2.4.2 Preparation 2 
For growth of bacteria, 5 mL LB media (10 g/L sodium chloride, 5 g/L yeast extract and 10 g/L 
tryptone) were inoculated with desired bacterial strain, followed by incubation at 37 °C in a 
shaking incubator (Platform shaker: Innova 2300, New Brunswick Scientific Co, Enfield, USA; 
Incubator: Wärmeschrank für Plattformschüttler, Mytron Bio- und Solartechnik GmbH, Heilbad 
Heiligenstadt, Germany) overnight. Afterwards the preparatory culture was transferred into 20 
mL of media*1 and incubated for 18 hours defined temperatures*2. Bacterial growth was stopped 
by temperature reduction to 4 °C and sterile filtration (0.2 µm) of the bacterial suspension. For 
conservation 0.05 (v/v) % sodium azide was added. Required endotoxin concentrations for 
endotoxin recovery studies were adjusted by dilution with depyrogenated water. 
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*Modification of growth conditions: 
1) LB media:    a) 100 % media 
b) 1 % (v/v) media in depyrogenated water 
    c) 100 % media plus 20 mM tris buffer 
d) 100 % media plus 20 mM EDTA 
2) Growth temperature:   i) room temperature (20 – 25 °C) 
    ii) 37 °C 
2.5 Sample handling 
2.5.1 Addition of endotoxin to a sample  
Samples were prepared in 5 mL borosilicate glass tubes with sample volumes of 1 mL per sample. 
Unless otherwise described, samples were spiked with 10 µL of endotoxin from E.coli O55:B5 (gel-
filtrated) out of a 10,000 EU/mL stock solution. Before adding the endotoxin spikes to the sample, 
the endotoxin stock solution was shaken at 1400 rpm for 10 minutes using Multi Reax shaker 
(Heidolph Instruments GmbH & Co.KG, Schwabach, Germany). After spiking, the samples 
including the endotoxin are shaken again at 1400 rpm for 60 seconds.  
2.5.2 Sample preparation before endotoxin detection 
To eliminate test interference and ensure validity of endotoxin detection assays, samples were 
vortexed for 2 minutes at 1400 rpm and diluted in depyrogenated water immediately prior to the 
measurement. The validity of the measurement was controlled by spiking of defined endotoxin 
amounts to the diluted samples (Positive Product Control (PPC)). Endotoxin determination in a 
sample was considered valid, if 50 to 200% of the spiked endotoxin (PPC) were recovered.   
2.5.3 Incubation of endotoxin in a sample 
For time dependent endotoxin recovery (hold time) studies, endotoxin was incubated in 
undiluted samples over time. If not otherwise specified, the pH of used buffer systems was 
adjusted to 7.5. After addition of defined endotoxins spikes to undiluted samples, the resulting 
solution was vortexed for 60 seconds at 1400 rpm. Samples were subsequently stored without 
further vortexing at defined temperatures (4° C (2 – 8 °C), RT (20 – 25 °C) and 37°C (35 – 40 °C) 
for a desired period of time.   
2.5.4 Preparation of endotoxin recovery kinetics 
Samples for kinetics can be prepared in two opposed sequential arrangements: Online mode 
(2.5.4.1) vs. reverse mode (2.5.4.2). Both preparations were used. Online mode has the advantage 
that the endotoxin spike in all samples is exactly the same. Disadvantage is that each time point 
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needs a new test and standard curve at different days. The advantage and disadvantage 
performing the reverse preparation are vice versa compared to the online mode.  
2.5.4.1 Online mode – kinetics (OM) 
Determination of endotoxin masking kinetics was prepared out of one stock solution using the 
online mode. The start of the kinetics was defined, when at least surfactant, chelator and 
endotoxin were combined and vortexed. In order to measure endotoxin at individual points of 
time, 10 µL of the corresponding sample were transferred to 990 µL of depyrogenated water after 
desired incubation period. Prior to the measurement, no further dilution was required. Samples 
were vortexed at least for 2 minutes at 1400 rpm before the individual time points were 
measured. The online method was used for all preparations of endotoxin masking kinetics, if not 
otherwise indicated. 
2.5.4.2 Reverse mode – kinetics (RM) 
Reverse endotoxin masking kinetics was prepared by spiking aliquots of a sample at different time 
points. The particular spiked and not spiked aliquoted were stored under equal conditions over 
time. The aliquot with the longest endotoxin incubation period was spiked first (e.g. 7 days prior 
to the measurement). Further aliquots with shorter incubation periods were spiked later in 
accordance with the respective incubation period. After spiking the time point zero aliquot, all 
samples were equivalently prepared and measured on the same assay.  
2.5.5 Endotoxin recovery and masking controls 
To control accuracy of the endotoxin spiked into the undiluted samples, equal amounts of 
endotoxin were spiked into depyrogenated water (positive control), mixed and identically 
incubated as the actual sample. For calculation of endotoxin recovery, the determined endotoxin 
concentrations in the actual sample is compared to the determined endotoxin concentration at 
time zero in the positive control and stated as percent.  
2.5.6 Sample preparation for demasking of endotoxin 
2.5.6.1 Preparation of demasking agents (working solution). 
For demasking, different molecules (Sodium citrate, calcium dichloride, BSA, SDS, alkyl-alcohols) 
and mixtures of them were used. Before addition of these molecules to the masked sample a 10-
fold concentrated working solutions of the desired component and concentration were prepared. 
Irrespective of the used alkyl alcohols, the components were dissolved in depyrogenated water. 
Alkyl alcohols were dissolved in 70% (v/v) ethanol. 
2.5.6.2 Sample treatment for demasking of endotoxin.  
Endotoxin demasking was performed by the addition of 100 μΙ of each demasking agent (2.5.6.1 
working solution) to the masked sample. The particular agents were sequentially added and 2 
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minutes vortexed after each addition. After addition of all demasking agents, the samples were 
incubated for 30 minutes at room temperature without vortexing.   
2.6 Limulus-based endotoxin detection assays 
2.6.1 Recombinant Factor C assays (rFC) 
2.6.1.1 EndoZyme® 
For detection of endotoxin, a recombinant Factor C test (EndoZyme ®), based on a homogenous 
test format, was used according to manufacturer’s instructions. The released amount of 
fluorescence substrate was measured fluorometrically at 440 nm (Excitation: 380 nm) with a 
FLx800 fluorescence microplate reader (BioTek Instruments GmbH, Bad Friedrichshall, Germany). 
All samples were measured in duplicate and average values were used for further calculations. 
Standard curves were fit using a four parameter logistic non-linear regression model. The 
detection limit of the assay was 0.005 EU/mL. EndoZyme was used in all experiments, if not 
otherwise indicated.  
2.6.1.2 EndoLISA® 
For detection of endotoxin, a recombinant Factor C test (EndoLISA ®), based on a heterogeneous 
test format, was used according to manufacturer’s instructions. The released amount of 
fluorescence substrate was measured fluorometrically at 440 nm (Excitation: 380 nm) with a 
FLx800 fluorescence microplate reader (BioTek Instruments GmbH, Bad Friedrichshall, Germany). 
All samples were measured in duplicate and average values were used for further calculations. 
Standard curves were fit using a four parameter logistic non-linear regression model. The 
detection limit of the assay was 0.005 EU/mL. 
2.6.2 Limulus Amebocyte Lysate assay (LAL) 
For endotoxin detection using Limulus Amebocyte Lysate, a kinetic chromogenic LAL assay 
(Kinetic-QCLTM) was used according to manufacturer´s instructions. The released amount of 
chromogenic substrate was measured spectrophotometrically at 405 nm with an Epoch2 
absorbance microplate reader (BioTek Instruments GmbH, Bad Friedrichshall, Germany). All 
samples were measured in duplicate and average values were used for further calculations. 
Standard curves were fit using a linear regression model. Detection limit of the assay was 0.005 
EU/mL.  
2.7 Silver stained SDS-PAGE 
Endotoxin samples (crude extracts, 2.4.1 preparation 1) were vortexed for 30 seconds. 40 µL of 
the sample were mixed with 10 µL SDS sample loading buffer (1.25 µL tris buffer, 0.5 mg sodium 
dodecylsulfate, 2.87 µL glycerol, 1.25 µL EDTA, 5 µg bromphenol blue and 0.25 µL 
mercaptoethanol) and boiled for 10 minutes.  18 µL of each sample were loaded onto a 20% 
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gradient tris-tricin gel. The SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis) was run in tris-tricine/SDS buffer at 130 V (Electrophoresis power supply: EPS 
301, Amersham Pharmacia Biotec, Uppsala, Sweden; Vertical Electrophoresis unit: Mighty small 
SE260, Hoefer Inc., Holliston, USA) for 90 minutes. For silver staining of the gel the following 
procedure was used:  
1) Fixation: Incubation of gel overnight in 150 mL of 25% (v/v) isopropanol and 7% (v/v) acetic 
acid.  
2) Oxidation:  Incubation of gel for 5 minutes in 75 mL depyrogenated water with 0.5 g of periodic 
acid and 1 mL of fixation solution (25% (v/v) isopropanol and 7% (v/v) acetic acid solution). 
3) Washing: Four times 5 minutes wash in depyrogenated water.  
4) Silver staining: 10 minutes in a solution containing 350 µL sodium hydroxide (8 M), 1 mL 
concentrated ammonium hydroxide (28%), 2 mL silver nitrate (20% (w/v) and 75 mL 
depyrogenated water.   
5) Washing: Four times 5 minutes wash in depyrogenated water were done.  
6) Development: 20 min in a solution containing 50 mL depyrogenated water, 50 mg citric acid 
and 50 µL formaldehyde (37%). Development was stopped using 10 % (v/v) acetic acid. 
2.8 Calculations and plots 
For calculation of endotoxin recovery, plotting of graphs and simulation of endotoxin recovery 
kinetics Microsoft Excel 2010, Version 14.0.7015.1000 was used. Sigmoidal experimental data 
points were fit using SigmaPlot 2001 for Windows Version 7.0. Calculation of standard curves for 
determination of endotoxin concentrations, Gen5 Data Analysis Software Version 2.05 from 
BioTek Instruments GmbH, Bad Friedrichshall, Germany was used. 
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3 Results and Discussion 
3.1 Masking of endotoxin in surfactant samples: Effects on Limulus-
based detection systems 
3.1.1 Introduction  
Bacteria and their breakdown products like endotoxins are ubiquitous[46]. The presence of 
endotoxins in aqueous compositions is an intractable problem, which severely threatens and 
limits the application of many compositions, in particular if intended for pharmaceutical use. This 
is especially true for parenteral administrated biopharmaceutical drug products. Therefore, there 
is a risk of endotoxin contamination in the production process of pharmaceutical drug products. 
To safeguard against potentially hazardous incorporation of endotoxin, measurements must be 
performed to exclude endotoxin from all steps and products used in the production process of 
parenteral drug products. For such measurements, a method of choice is the LAL assay. Since 
decades, these assays are positioned in quality control of pharmaceutical production and have 
been proven to be a sensitive measure for endotoxins. However, some reports have shown that 
detection of endotoxins is not always suitable in complex samples[47], [48]. One reason for 
inadequate detection of endotoxin is interference of sample constituents with the enzymatic 
reaction of the Limulus-based detection system. In this case, certain components (e.g. heavy 
metals, protease inhibitors) can directly disturb enzyme activation of the detection system, which 
is called test interference[49]. This phenomenon is well known and to identify test interference, 
positive product controls (PPC) are performed. To this end, a known amount of endotoxin is 
added to the sample and immediately measured. A test is considered valid if the spiked endotoxin 
is recovered in a range of 50 to 200%. If the validity criterion is not fulfilled, it is recommended to 
overcome interference by suitable sample treatments such as dilution, filtration, neutralization, 
dialysis or heating[40]. Another potential reason for inadequate endotoxin detection is the 
interaction of endotoxin itself with matrix components of the sample. For instance, it has been 
reported that endotoxin can interact with blood components[50], proteins[47] or amphiphilic 
molecules[51], [52], resulting in a significant change of endotoxin activity. Notably, approaches 
which eliminate test interference problems are not effective in overcoming such effects[47]. In 
the 1990´s Greaves and co-workers already differentiated between dilution-dependent and 
dilution-independent interference in environmental samples[53]. 
In the recent past, inadequate endotoxin detection has been observed in biopharmaceutical drug 
products[54]. In such cases, the APIs are mainly proteins[55], which are capable of intrinsic 
binding to endotoxin as previously described by Anspach and co-workers[47]. The inadequate 
detection of endotoxin might be explained by protein-endotoxin interactions, but furthermore, 
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therapeutic proteins are usually stabilized by excipients, like nonionic surfactants and certain 
buffer components[56]. Surprisingly, endotoxin spiking experiments in formulations that lack the 
API resulted in LER. Such observations of disturbed endotoxin determinations in 
biopharmaceutical products occurred over time and the related risk of undiscovered endotoxin 
contamination events compelled us to study the impact of common formulation components on 
the detectability in Limulus-based detection systems.  
Therefore, crucial formulation components of common biopharmaceuticals are extracted from 
popular biopharmaceutical drug products (table 1) and endotoxin recovery out of such buffer 
systems containing single and multiple components is investigated. Due to the expected time-
dependency of LER, the end-point of the reaction is determined by using different sample 
incubation temperatures. While multi-parameter interactions between surfactants, complex 
forming agents and endotoxin are assumed, the particular influence of the buffer components on 
the detectability of endotoxin is focused. Hence, the impact of pH in a sample, different buffer 
systems and the effects of different nonionic surfactants are studied. Finally, various endotoxin 
concentrations are added to a LER causing formulation to evaluate the masking capacity of such 
a sample.  
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3.1.2 Results 
For analysis of LER, undiluted samples were spiked with defined amounts of endotoxin and 
incubated over time. With regard to biopharmaceutical drug products, single and mixtures of 
common formulation components were examined to identify critical components or 
combinations affecting endotoxin detection. Endotoxin recovery in the presence of different 
formulation components is shown in table 2. 
Table 2 Endotoxin recovery out of single and multiple component samples 
Endotoxin recovery over time in presence of single and multiple formulation components is shown. 
Samples were spiked with an endotoxin amount of 10000 EU/mL. Endotoxin was detected after 
preparation (approx. 45 min., T0)) and after sample incubation of seven days (T7) at room temperature. 
Prior to the measurement samples were diluted up to 1:10000.  
Sample: Formulation components: T0 Recovery [%] T7 Recovery [%] 
1 H2O 100 94 
2 Sodium citrate 125 94 
3 Sodium phosphate 95 69 
4 Polysorbate 20 91 79 
5 Sodium citrate + polysorbate 20 1 0 
6 Sodium phosphate + polysorbate 20 52 0 
 
The recovery was determined after endotoxin spiking of the samples without incubation (T0) and 
after sample incubation for seven days (T7) at room temperature (RT). Samples 2, 3 and 4, 
containing only single component additions showed no significant loss of activity over time, 
according to a validity criteria of 50 to 200% of endotoxin recovery. In contrast, endotoxin could 
not be detected in samples containing both buffer and surfactant (samples 5 and 6) after an 
incubation period of seven days. This result shows that endotoxin recovery is substantially 
affected by the sample incubation period and mixture of formulation components. 
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Figure 7 Endotoxin recovery kinetics in citrate-polysorbate formulations 
The endotoxin recovery is plotted as a function of the incubation time. The different curves indicate 
incubation temperatures at 35-40°C ( ● ), 20-25°C (  ) and 2-8°C (  ). 100 EU/mL endotoxin were 
added to samples containing 10 mM sodium citrate and 0.05 % polysorbate 20 and incubated for 
different time periods (reverse mode, 2.5.3.2). For detection (A) kinetic chromogenic LAL tests and (B) 
recombinant Factor C tests were used. The error bars reflect the standard deviation of three 
independent replicates (n=3) of the sample. The replicates were measured on the same microtiter 
plate. 
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To examine the time-dependency of LER more in detail, kinetics of endotoxin recovery in samples 
containing polysorbate 20 and sodium citrate was analyzed. Figure 7 shows the endotoxin 
recovery of three identical samples as a function of time at different incubation temperatures 
(4°C, RT and 37 °C) using a Limulus amebocyte lysate (LAL) test (A) and a recombinant Factor C 
test (B) for detection. After approximately 24 hours of incubation, all samples showed low 
endotoxin recovery in both detection systems. This result clearly indicates that this phenomenon 
is independent of the test system. Furthermore, the loss of activity was significantly accelerated 
with increasing incubation temperature.   
Together, these experiments show that the combination of a buffer system and a surfactant 
results in LER over time. Thus, the impact of different buffer systems was studied (Figure 8). In 
order to investigate pH dependency of endotoxin recovery after sample incubation, defined 
compositions under different pH conditions were studied (figure 8A). In the absence of 
surfactants, the variation of pH had no impact on endotoxin detection. This confirmed again the 
previous results (table 2). However, in the presence of polysorbate the recovery significantly 
decreased at pH values higher than pH 2 (citrate system) and pH 5 (phosphate system), 
respectively. The transition to higher pH values hampered endotoxin recovery. In addition, the 
diverging curve progressions (Figure 8A) indicate an intrinsic effect of each particular buffer 
system. Hence, endotoxin recovery kinetics using different buffer systems such as 
ethylenediaminetetraacetic acid (EDTA), citrate and phosphate were studied (Figure 8B). 
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Figure 8 Impact of buffer system on endotoxin recovery 
(A) Endotoxin recovery is shown as a function of the pH. The pH varied in a range from 1 to 9 and 
incubation was at RT for seven days. 100 EU/mL of endotoxin were added to solutions containing 0.05 
wt % polysorbate 20 plus 10 mM citrate (  ), 0.05 wt % polysorbate 20 plus 10 mM phosphate (  ), 
citrate only (  ) and phosphate only (  ). The error bars reflect the standard deviation of three 
independent replicates (n=3) of the sample. The replicates were measured on the same microtiter 
plate.     ……………………………………………………                                                                                     
(B): Endotoxin recovery is plotted as function of incubation time using different buffer systems. Sample 
incubation was at RT. 100 EU/mL of endotoxin were added to solutions containing a buffer (5 mM EDTA 
(  ), 10 mM sodium citrate (  ) or 10 mM sodium phosphate (  )) and 0.05 wt % polysorbate 20 
(reverse mode, 2.5.3.2). The error bars reflect the standard deviation of three independent replicates 
(n=3) of the sample. The replicates were measured on the same microtiter plate. 
The endotoxin recovery in the described buffer systems is plotted as a function of time. The 
system containing EDTA showed a rapid loss of activity. The loss of activity was slower under citric 
conditions and slowest under phosphoric conditions. After six hours, recovery was below 30% 
under each condition. As confirmed before, surfactants are significantly involved in reducing the 
activity of endotoxin in common detection systems. Therefore, the effects of different surfactants 
at constant buffer and endotoxin conditions were examined. In figure 9, the endotoxin recovery 
out of surfactant solutions (polysorbate 20, polysorbate 80 and octoxynol 9) in the presence and 
absence of citrate are plotted as a function of surfactant concentration. In general, all used 
surfactants substantially reduced endotoxin detectability in the presence of citrate after seven 
days of incubation.  In absence of citrate, only octoxynol 9 showed low recovery at relatively high 
concentrations after the incubation period. Without incubation, endotoxins were detectable in 
all cases (> 50%), except using highest octoxynol 9 concentration including citrate.  
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Figure 9 Surfactant dependent endotoxin recovery 
Endotoxin recovery is shown as a function of the particular surfactant concentration. 100 EU/mL of 
endotoxin were added to solutions containing various amounts of (A) polysorbate 20, (B) polysorbate 
80 or (C) octoxynol 9. Endotoxin recoveries were determined in the presence of 10 mM sodium citrate 
immediately after preparation (  ) and after incubation for seven days at RT (  ). In parallel endotoxin 
activities were determined in the absence of citrate, without incubation (  ) and after incubation   
(  ). 
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Summarizing the results above, nonionic surfactants and complex forming buffer components in 
combination cause a significant perturbation of endotoxin detection in Limulus-based detection 
systems. The resulting LER is time-dependent and may solely occur after a certain period of time. 
For a final evaluation, the masking capacity was examined. Endotoxin was titrated into samples 
containing a citrate buffer system and polysorbate.  
 
Figure 10 Endotoxin masking capacity of citrate-polysorbate 20 formulation 
Detectable endotoxin concentration is shown in relation to the spiked endotoxin concentration. 
Defined amounts of endotoxin were added to solutions containing 0.05 wt % polysorbate 20 and 10 
mM sodium citrate and incubated for seven days at 4 °C. Endotoxin spikes were prepared out of a LPS 
stock solution containing 10-6 EU/mL.  
Figure 10 shows the endotoxin masking capacity of such a particular matrix. Spiked endotoxin 
contents of up to 250 EU/mL resulted in no endotoxin recovery after seven days of incubation. 
Medium and high-level spikes resulted in very low (<1%) and low endotoxin (< 5%) recovery. This 
result illustrates a high masking capacity of common formulation matrices and suggests the need 
for vigilance in BET under such conditions. 
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3.1.3 Discussion 
BET is a standardized control instrument in pharmaceutical microbiology. To check the absence 
of test interference and validity of a measurement, PPCs are regularly used according to 
pharmacopoeial requirements. However, since the observation of inconsistencies during BET, 
although valid PPC are given, users are partly asked by regulators to establish additional test 
procedures for storing samples and demonstrating the stability of assayable endotoxin 
contents[57]. Consequently, there are two different control procedures in BET. The first are PPCs, 
which are used to identify test interference. Thereby, defined contents of endotoxin are spiked 
into diluted samples immediately before the measurement is started. The measurement is 
considered valid, when 50 to 200% of this spike is recovered. The second procedure to investigate 
LER is the application of “hold time” or “endotoxin recovery” studies. In this case, defined 
contents of endotoxin are spiked into undiluted samples and the spike is incubated for a certain 
period of time in the sample before the actual endotoxin measurement.  A sample is popularly 
classified as LER, when less than 50% of the spike is recovered over time.  
Basically, test interference directly affects the detection system, but can be overcome by dilution. 
In the case of LER, sample dilutions up to a factor of 10,000 could not overcome inadequate 
recovery (Table 2), demonstrating that LER is dilution independent and therefore not caused by 
test interference. Furthermore, after short incubation periods of endotoxin in the sample, the full 
endotoxin content could be recovered, showing the functionality of the detection system (Figure 
7). These findings confirm a previous observation, namely that under certain conditions the 
interference in Limulus-based detection methods is dilution independent. In this case, it is 
assumed that the aggregate conformation of LPS is affected and not the detection system 
itself[53]. Hence, the results above indicate that the phenomenon of LER is also caused by 
alterations in the aggregate conformation of the endotoxin, meaning the endotoxin is masked. 
This is also supported by the time-dependent appearance of LER, while test interference appears 
immediately and is therefore time-independent. This time-dependent behavior of LER can be 
illustrated by an alteration of the supramolecular structure of the amphiphilic LPS. In general, the 
process of aggregation of amphiphilic molecules can be very variable with respect to time-scales 
for structural changes, which range from sub-microseconds to several days, weeks and even 
month[58]. This time-dependent occurrence of LER might also explain confounding experimental 
results in pharmaceutical industries (results not published), in which the LER phenomenon was 
not observed, although masking conditions were present. 
3.1.3.1 Effects of complex forming agents 
The results demonstrate that endotoxin recovery is affected by the formulation components 
themselves, even if the active pharmaceutical substance, such as a protein, is absent. The 
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simultaneous presence of a nonionic surfactants and complex forming components (chelator) 
suffices to decrease the detectability of endotoxin. The presence of only one of the formulation 
components does not effectively disturb endotoxin recovery. These findings confirm former 
assumptions of endotoxin disaggregation [59], [60] and explain the interdependent interaction of 
surfactant and chelator on endotoxin. Due to the amphoteric and amphiphilic nature of LPS 
(Figure 3), complex forming agents disturb the electrostatic interactions and surfactants 
potentially disturb the hydrophobic interactions in endotoxin aggregates. Certainly, to disturb the 
supramolecular structure of endotoxin a reduced rigidity is beneficial. The rigidity is controlled by 
the salt form of LPS, which again involves the presence of multivalent cations like Ca2+.[61], [62] 
Consequently, it can be assumed that complex forming agents are in competition with negatively 
charged patches of the endotoxin. Therefore, the salt bridges between LPS molecules are 
disturbed, which should result in a reduced rigidity of endotoxin aggregates, which in turn 
facilitates changes in the supramolecular structure. In the presence of EDTA the recovery drops 
faster than in the presence of citrate or phosphate based buffer systems (Figure 8B). Using buffer 
components with higher metal complex forming capabilities accelerate masking kinetics. Thus, 
the chelating capability of the buffer component is crucial. The related metal complex formation 
constants are directly proportional to the denticity of the ligand (rule of thumb[63]). A 
hexadentate ligand like EDTA forms more stable metal complexes than a tridentate ligand like 
citrate. Furthermore, the equilibrium complex formation ability and the complex stability of a 
chelator are pH dependent. At low pH values, protons are in competition with cations, which 
hamper formation of metal complexes[64]. Consequently, LER is affected by the free 
concentration of protons reflected by pH, which is controlled by the buffer system and its 
particular acid dissociation constant. This explains the pH dependent endotoxin recovery in 
different buffer systems (Figure 8A).  
3.1.3.2 Effects of surfactants on LER 
As shown above, complex forming components alone do not result in inadequate endotoxin 
detection, additional amphiphilic components like surfactants are necessary. Due to the fact that 
LPS itself are amphiphilic, these tend to aggregate, driven by the low solubility of hydrophobic 
fatty acids of lipid A in an aqueous solution[65]. Thus, LPS exhibit certain supramolecular 
structures, which influence detectability in Limulus-based detection systems[66]. Structural 
transitions of amphiphilic systems are affected by a large variety of physical and chemical 
parameters. One major principle to control these structures is the head group repulsions of self-
assembling molecules. They can be affected by co-surfactants, electrolytes, and amphiphilic 
counter ions[67]. If the masking surfactant (e.g. polysorbate) intercalates between LPS molecules 
resulting in reduction of head group repulsions, the establishment of a new equilibrium is favored 
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and the supramolecular structure of LPS is altered. The interaction of nonionic surfactants with 
LPS aggregates is favored if the LPS aggregates possess a certain degree of rigidity. The latter is 
controlled, to some extent, by ionic interactions as described above. To this end, after the 
addition of surfactants and chelators to LPS solutions, the supramolecular structure of LPS is 
changed into a structure with a lower affinity to the endotoxin sensitive Factor C of the Limulus-
based detection system resulting in the measurement of a lower activity. Such a structure could 
be disaggregated LPS due to a molecular excess of surfactants. This hypothesis fits well to the 
observation of Mueller et al., who have shown that disaggregated LPS molecules (“monomers”) 
are substantially less active than aggregated LPS in the detection system used[66]. Additionally, 
Tan et al. proposed a cooperative binding mechanism of LPS to Factor C, which consequently 
requires more than one LPS molecule in close spatial arrangements[68].  On the other hand, it 
has been shown that monomeric LPS show a higher potency in activating LAL assays than 
aggregated LPS[27]. Under these circumstances, the inadequate detectability might has steric 
reasons, in which the activating spots of the LPS (lipid A) are hidden by surfactant molecules and 
are not accessible for Factor C. 
3.1.3.3 Potential two-step reaction mechanism of LER 
In summary, we propose a two-step mechanism of endotoxin masking. Figure 11 illustrates the 
effects of chelating buffer components and nonionic surfactants on endotoxin. In this mechanism 
the equilibrium LPS structure is shifted to an altered supramolecular structure.  
 
Figure 11 Two-step mechanism of endotoxin masking 
Potential reaction mechanism of endotoxin masking, caused by complex forming agents and surfactants 
is schematically illustrated. In a first step, pure endotoxin aggregates are disturbed by chelators 
reducing the rigidity of the aggregate. Then, surfactants interact with endotoxin by forming mixed 
aggregates. 
In its natural state, LPS monomers tend to aggregate due to the hydrophobic interactions 
between the lipid A molecules. Additional ionic interactions formed by divalent cations and 
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negatively charged substitutes (e.g. phosphates) of the LPS increase the rigidity of aggregates. By 
adding a complex forming agent (I), the salt bridges formed by divalent cations (e.g. Mg2+) and 
LPS are destabilized, leading to a reduced rigidity of the aggregate. The additional presence of a 
surfactant (II) can then change the initial supramolecular structure by formation of mixed 
aggregates. This structural change leads inevitably to a certain change in detectable activity, as 
endotoxin activity is dependent on its supramolecular structure. Due to the common molar excess 
of complex forming agent and surfactant (micromolar range) compared to endotoxin content 
(nanomolar range), mixed surfactant micelles containing monomerized LPS are the most probable 
resulting supramolecular structure.  
Together, this study confirmed the phenomenon of LER in Limulus-based detection systems and 
exemplifies a potential mechanism of endotoxin masking. Due to the time-dependency of 
masking, the unknown period of endotoxin presence during a potential event of endotoxin 
contamination in a sample defines the chance of endotoxin recovery. Hence, LER is under control 
of kinetics that governs the formation of mixed endotoxin-surfactant aggregates, which make 
them less prone to activate the enzymatic reaction of Limulus-based detection systems. Capacity 
experiments have shown that commonly used excipients are capable of masking hazardous 
amounts of endotoxin. Consequently, the phenomenon of LER has to be especially considered 
during quality control of drug products including surfactant and complex forming agents. In order 
to further investigate the time-dependent masking behavior of endotoxin, detailed reaction 
kinetics is studied in the next chapter (3.2). 
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3.2 Endotoxin Masking: A kinetically controlled reaction mechanism 
3.2.1 Introduction 
In the previous chapter (3.1), the phenomenon of LER was studied in common biopharmaceutical 
product matrices and it is supposed that LER is caused by the interaction of sample matrix and 
endotoxin, resulting in masking of endotoxin. Basically, LPS aggregate due to their amphiphilic 
nature and in turn form certain supramolecular structures[70]. Yet, during the transition from 
detectable to undetectable (masked) endotoxin a change in its supramolecular structure is 
probable. Moreover, a disaggregation of LPS may occur during masking. With regard to parenteral 
drug products, regulators consider this phenomenon as a potential safety issue due to the 
possible underestimation of critical endotoxin levels in a sample[54]. To investigate if a product 
is affected by LER, an industrial guideline for BET suggests hold time studies[57], which intend to 
incubate known amounts of endotoxin over time in undiluted products prior to the actual test 
procedure.  
The aim of such hold time studies is to prove assayability of endotoxin in a particular sample over 
time. In order to provide a better understanding of the LER mechanism and in turn to improve 
efficiency in planning of such hold time studies the time-dependent appearance of LER is analyzed 
in detail. Therefore, a common formulation matrix containing sodium citrate and polysorbate 20 
is used in the present study. This matrix was chosen, because it is a common formulation 
composition for biopharmaceutical drugs products[56]. Furthermore, such a composition reflects 
the minimum factors responsible for endotoxin masking and should therefore help to elucidate 
the driving forces of endotoxin masking. Apart from the temperature dependency of a reaction, 
the change in concentrations during chemical reactions is often directly proportional to the rate 
of a reaction[71]. Derivation of a rate law according to the underlying masking reaction enables 
prediction of the reaction rate depending on a given product formulation and help to plan sample 
hold time periods for identification of LER. In order to determine a rate law of the reaction, 
endotoxin recovery kinetics is recorded using different concentrations of citrate, polysorbate and 
endotoxin. The variation of concentrations is used to identify whether there are certain reactants 
controlling the reaction rate. Furthermore, the rate determining step in the proposed two-step 
reaction mechanism (3.1.3.3) is specified and the derived reaction law is and used for the 
simulation of endotoxin masking kinetics.  
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3.2.2 Results 
Endotoxin masking, caused by the simultaneous presence of surfactants and complex forming 
agents, has been shown in the previous chapter (3.1). In these studies, mixtures of formulation 
components influenced the occurrence of masking. To analyze whether the preparation of the 
samples affects endotoxin masking, kinetics with different order of sample preparations was 
investigated. Two of the three components (polysorbate, sodium citrate and endotoxin) were 
pre-incubated overnight and masking kinetics was started by addition of the third component 
(Figure 12). As expected, all preparations were affected by LER, but diverging kinetics are 
observed.  Endotoxin pre-incubated with sodium citrate shows the fastest masking kinetics and 
pre-incubation of polysorbate with sodium citrate shows the slowest kinetics. Endotoxin pre-
incubated with polysorbate shows likewise slow kinetics. Based on the accelerated reaction 
kinetics by pre-incubation of endotoxin with sodium citrate, the interaction between endotoxin 
and sodium citrate appears to be the time limiting reaction step. The large error bars reflect test 
variables of Limulus-based assays, but also the experimental setup. Depending on exact ambient 
temperatures and hands on time for sample preparation including spiking, mixing as well as 
vortexing may influence reaction kinetics. 
 
Figure 12 Endotoxin recovery depending on order of matrix component and LPS addition 
Endotoxin recovery is plotted as a function of incubation time. 100 EU/mL endotoxin were spiked to 
solutions containing 0.05 wt % polysorbate 20 and 10 mM sodium citrate. The particular kinetics was 
generated by different sequential arrangements during sample preparation at RT. In the first kinetics 
(dark grey triangles (  )) LPS and sodium citrate were pre-incubated (overnight) and polysorbate was 
added at time zero (0 min) to start the reaction. In the second kinetics (light grey squares (   )) LPS and 
polysorbate were pre-incubated (overnight) and sodium citrate was added at time zero (0 min). In the 
third kinetics (black diamonds (  )) sodium citrate and polysorbate were pre-incubated (overnight) 
and LPS was added at time zero (0 min). For calculation of the data points the mean values of two 
(LPS/sodium citrate and LPS/polysorbate pre-incubation) and three (polysorbate/sodium citrate pre-
incubation) individually performed repetitions of the kinetics were used and the error bars reflect the 
corresponding standard deviations. For a better comparison of independent measurements, the data 
was normalized and the starting points were set to 100 %. 
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In order to further analyze the driving forces of this endotoxin masking effect, recovery kinetics 
using different concentrations of the reactants were analyzed. First of all, recovery of different 
endotoxin concentrations (50, 500 and 5000 EU/mL) were studied under constant 
polysorbate/citrate conditions (Figure 13). The recovery over time showed no significant 
difference using different endotoxin concentrations, indicating that masking is independent of 
the initial endotoxin concentration. After 10 minutes of incubation, all recoveries are above 50% 
and after 45 minutes all recoveries are below 7%. 
 
Figure 13 Endotoxin recovery kinetics depending on LPS concentration 
Endotoxin recovery is plotted as a function of incubation time. Varying contents of endotoxin were 
added to samples containing 0.05 wt % polysorbate and 10 mM sodium citrate at RT. The black columns 
reflect 5000 EU/mL, grey columns 500 EU/ml and white columns 50 EU/mL. For calculation of the data 
points the mean values of two individual prepared kinetics were used and the error bars reflects the 
corresponding standard deviations. For a better comparison of independent measurements, the data 
was normalized and the starting points were set to 100 %. 
Thereafter, masking of endotoxin was analyzed using reduced concentrations of polysorbate and 
sodium citrate (Figure 14A). The recovery of endotoxin in a sample containing 0.05 wt % 
polysorbate and 10 mM sodium citrate was below 1 % after one hour of incubation. Using a 
sample matrix of 0.0125 wt % polysorbate and 2.50 mM sodium citrate the endotoxin recovery 
was not reduced after one hour of incubation, but after incubation of 20 hours, the endotoxin 
recovery was very low, too. Using a sample matrix containing 0.0008 wt % polysorbate and 0.16 
mM sodium citrate, no significant decrease in recovery of endotoxin is observed over the analyze 
period of time (20 hours). Thus, masking can be delayed or even avoided, when the entire sample 
matrix is diluted before spiking the endotoxin. Furthermore, endotoxin recovery was determined 
in samples, in which only the polysorbate concentration (0.0500, 0.0125 and 0.0008 wt %) was 
reduced (Figure 14B).  
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Figure 14 Endotoxin recovery kinetics depending on concentration of matrix components 
A) Endotoxin recovery is plotted as a function of incubation time. 100 EU/mL of endotoxin were spiked 
to samples containing polysorbate 20 and sodium citrate at RT. The three different colored columns 
reflect different polysorbate and sodium citrate concentrations. The set of black columns correspond 
to 0.0500 wt % polysorbate and 10.00 mM sodium citrate, the set of grey columns correspond to 0.0125 
wt % polysorbate and 2.50 mM sodium citrate and the set of white columns correspond to 0.0008 wt 
% polysorbate and 0.16 mM sodium citrate.                                                             …………………………………………… 
B) Endotoxin recovery over time in samples containing polysorbate, sodium citrate and LPS is shown. 
The different colored columns reflect different polysorbate concentrations. The set of black columns 
correspond to 0.0500 wt % polysorbate, the set of dark grey columns correspond to 0.0125 wt % 
polysorbate and the set of light grey columns correspond to 0.0008 wt % polysorbate. The 
concentrations of endotoxin (100 EU/mL) and sodium citrate (10 mM) as well as temperature (RT) were 
kept constant. 
Concentrations of the other components (endotoxin and citrate) were kept constant. In this case, 
the recovery kinetics is similar within a given measurement uncertainty. The endotoxin recovery 
is below 2 % independent of the polysorbate concentration after one hour of incubation. This 
result differs from the previous result, in which the endotoxin was recovered after one hour of 
incubation (> 100%) at reduced polysorbate and citrate concentrations (Figure 14A). Although the 
polysorbate concentration was comparably titrated in both cases, the sodium citrate 
concentrations were different among the two experiments (Figure 14: A vs. B). This again 
indicates that the role of sodium citrate is crucial within the given experimental conditions. Due 
to the fact that sodium citrate is capable of forming metal complexes with divalent cations, 
endotoxin recovery kinetics was examined in the presence of divalent cations (Figure 15A). Here, 
masking kinetics is delayed in the presence of 1 mM magnesium dichloride compared to the 
samples without magnesium dichloride. In the presence of 5 mM magnesium dichloride, no 
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reduced endotoxin recovery is observed within the analyzed time scale. Importantly, the 
magnesium dichloride was added to the samples prior to endotoxin. In a further experiment, 
magnesium dichloride was added to the polysorbate/sodium citrate matrix 20 minutes after start 
of the reaction (figure 15B). Although the recovery of endotoxin was already reduced at this point 
of time, no further decrease of endotoxin recovery was observed after addition of magnesium 
dichloride. In comparison, the sample without supplementary addition of divalent cations was 
masked as expected. Hence, the addition of magnesium dichloride can stop endotoxin masking 
and keep the recovery constant at the actual level. Notably, the original endotoxin activity could 
not be retrieved after the addition of magnesium dichloride. 
 
 
Figure 15 Endotoxin recovery depends on the presence of divalent cations 
A) Endotoxin recovery is plotted as a function of time in samples containing polysorbate 20, sodium 
citrate, endotoxin and magnesium dichloride. The different colored columns reflect different contents 
of magnesium dichloride (0 mM (white columns), 1 mM (grey columns), 5 mM (black columns)). 
Concentrations of polysorbate (0.05 wt %), sodium citrate (10 mM) and endotoxin (100 EU/mL) as well 
as temperature (RT) were kept constant.                                                   ……………………… 
B) Endotoxin recovery is plotted as a function of time in a sample containing 0.05 wt % polysorbate, 10 
mM sodium citrate and 100 EU/mL endotoxin (white columns). After 20 minutes, the sample was 
divided into two equivalent aliquots (1 mL each), whereof one aliquot was treated once by the addition 
of 20 mM (20µL of 1 M) magnesium dichloride and the other fraction were continued without 
treatment. Endotoxin recovery of the treated fraction is expressed by the black columns. 
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Obviously, there is a relation between masking kinetics and complex formation. For deeper 
analysis of this effect, masking kinetics using three different citrate concentrations (5, 20, and 80 
mM) were recorded (Figure 16). A distinct acceleration of masking by increasing the citrate 
concentration in the sample from 5 mM to 80 mM is observed. Furthermore, the experimental 
data points are compared to a model curve using an exponential decay function, in which the 
endotoxin recovery [LPSd] is calculated as a function of time t: 
[LPSd]=[LPSd]0*exp(-[Ci]kt)        (1) 
The parameters of this function were set in analogy to the experimental conditions. Endotoxin 
recovery at time 0 [LPSd]0 was set to 100%, time t was given in minutes and k was chosen by 
chance and set to 7. The sodium citrate concentrations [Ci] were set to 0.005, 0.020 and 0.160 
mol/L in the particular curves. The simulated curves are in good agreement with the experimental 
data, illustrating that the endotoxin masking kinetics is depending on the sodium citrate 
concentration. Derivation of this model function is discussed in chapter 3.2.3.1 Simulation of LER 
kinetics. 
 
Figure 16 Sodium citrate concentration determines endotoxin recovery 
Endotoxin recovery is plotted as a function of incubation time. 100 EU/mL of endotoxin were added to 
samples containing varied sodium citrate concentrations (5 mM ( ), 20 mM ( ), 80 mM ( ). 
Concentration of polysorbate 20 (0.05 wt %) and temperature (RT) were kept constant. For the 
corresponding simulation (  ), an exponential decay function was used (Equation 1). For a better 
comparison of independent measurements, the experimental data was normalized and the starting 
points were set to 100 %. 
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Summarizing the kinetics above, 100 EU/mL endotoxin will be substantially masked within 90 
minutes of sample incubation in the presence of at least 5 mM sodium citrate and 0.05 wt % 
polysorbate 20. Variation of the polysorbate concentration (Figure 14B) showed no significant 
acceleration or deceleration of the masking kinetics. In contrast, the increase of sodium citrate 
concentration (Figure 16) resulted in considerably accelerated endotoxin masking kinetics. To 
determine, whether there is a minimum citrate concentration for endotoxin masking, sodium 
citrate was titrated under constant polysorbate and endotoxin concentrations and the samples 
were incubated for seven days prior to endotoxin measurement (Figure 17). According to the 
previous kinetics, it was assumed that equilibrium of the masking reaction will be established 
after seven days. Plotting endotoxin recovery as a function of citrate concentration results in a S-
shaped data point’s progression, from full recovery at a constant level to no recovery of endotoxin 
depending on the citrate concentration. This behavior indicates that there is a limiting 
concentration of citrate to facilitate endotoxin masking which can be deduced from the transition 
point. In order to determine this citrate concentration, the experimental data set was fitted using 
the following nonlinear fit function:  
y(x)=a/(1+(x/x0)b)         (2) 
 
Figure 17 Endotoxin recovery depends on sodium citrate concentration under equilibrium conditions 
Endotoxin recovery is plotted as a function of sodium citrate concentration. 50 EU/mL endotoxin and 
0.05 wt % polysorbate were incubated with varying sodium citrate concentrations for seven days at RT 
prior to the measurement. For calculation of the data points the mean values of two individual 
performed repetitions were used. Error bars reflect standard deviations. For the corresponding fit a 
logistic function with three parameters is used (Equation 2). 
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A three parameter logistic function (Equation 2) was chosen, because it reflects a sigmoid curve 
progression and the transition point can be determined easily. The resulting sigmoid curve fit 
shows endotoxin recovery as a function of sodium citrate concentration. The calculated 
coefficients “a” equates 125.66, “b” equates 1.50 and “x0“ equates 0.06. The transition point (x0) 
of the curve can be assumed as the limiting citrate concentration and corresponds to a citrate 
concentration of 0.06 mM under given conditions (Figure 17). In consequence, masking of 
endotoxin does not occur in solutions containing polysorbates and less than 0.06 mM sodium 
citrate.   
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3.2.3 Discussion 
Endotoxin masking (LER) has been identified as a time-dependent phenomenon and in contrast, 
test interference occurs instantly[72], [73]. The latter can be therefore clearly distinguished from 
masking. The results presented here show that endotoxin masking in a sample may not be 
discovered when the spike is added to the diluted sample, because the original ability of the 
sample matrix for masking may be weakened or even avoided, when the concentration of a matrix 
component is reduced. For example, Figure 14A shows a significant delay in time until LER is 
recognized when endotoxin is spiked in a diluted sample. Due to the fact that test interference is 
considered since decades, common and compendial BET procedures are trimmed to identify and 
overcome test interference, but these procedures are not prone to discover and overcome time 
dependent masking effects. Therefore, it is important to universally include endotoxin spikes into 
undiluted samples to actual test procedures as well as careful consideration of suitable incubation 
conditions. In 2012, US FDA has already updated their guidelines for BET[57] and European 
Pharmacopoeia includes hold time experiments in the coming 9th edition (2017). To this end, it is 
necessary to generally extend and harmonize worldwide compendial test procedures to 
thoroughly identify the endotoxin masking capability of a sample. 
However, to control the phenomenon of LER, understanding of the masking mechanism is a key 
factor. There are several examples showing that endotoxins interact with a variety of 
components, including proteins[47], surfactants[51] or nano particles[74], but the reaction 
mechanism remains to be elucidated. Most likely, due to the amphiphilic and amphoteric 
character of LPS[9], hydrophobic and electrostatic interactions are involved. According to 
previous assumptions the two-step masking mechanism (3.1.3.3) may formally be described as 
follows: 
[M-LPS]+[Ci] [LPS]+[M-Ci]        (3) 
Chelating buffer components (Ci) destabilize salt bridges formed between divalent cations (M) 
(e.g. magnesium) and negatively charged substitutes (e.g. phosphates) of LPS (LPS) (Equation 3). 
[LPS] +[P]  [P-LPS]         (4) 
Subsequently, non-ionic surfactants (P) (e. g. polysorbate) can interact with LPS and result in an 
altered supramolecular structure of LPS (P-LPS) (Equation 4), leading to a change in detectable 
activity. For a deeper understanding of this mechanism, identification of the time depending 
reaction step is necessary. To this end, the kinetics of endotoxin masking was studied in the 
presence of citrate and polysorbate. Interestingly, pre-incubation of LPS with citrate and the 
subsequent addition of polysorbate resulted in very fast masking kinetics. However, pre-
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incubation of LPS with polysorbate, and subsequent addition of citrate resulted in somewhat 
slower kinetics (Figure 12). Furthermore, masking kinetics with increased citrate concentrations 
and constant polysorbate concentrations (Figure 16) show accelerated reaction rates. In turn, a 
variation of polysorbate concentration under otherwise identical conditions had no significant 
impact on the reaction rate (Figure 14B).  As a consequence, the first step of the reaction 
mechanism (Equation 3) seems to control the reaction rate and depends on the citrate 
concentration. 
3.2.3.1 Simulation of LER kinetics 
To establish a simplified model describing the reaction rate, only the first step of the reaction 
(Equation 3) will be considered. The second step of the reaction (Equation 4) can be neglected, 
because this step is fast and does not limit the reaction rate within the given conditions. Basically, 
the reaction rate [R] is given by the change of detectable endotoxin [LPS d] as a function of time t 
and can be expressed as follows: 
R = d[LPS d] /dt          (5) 
In addition, the results implicate that the reaction rate depends on the citrate concentration 
(Figure 16). Generally, it is supposable that the reaction rate is also depending on the LPS 
concentration, although the results indicate no concentration dependency of LPS (Figure 13). 
Thus, the reaction rate R of endotoxin masking is described as depending on detectable LPS [LPS 
d] and the citrate concentration [Ci] resulting in the following equation: 
R = k[LPS]d[Ci]                   (6) 
Equalizing equation (5) and (6) results in a differential function, which is the basis for a second 
order reaction kinetics: 
d[LPS d] /dt = k[LPS d] [Ci]                (7) 
After rearrangement and integration of equation (7), the rate equation of a second order reaction 
is obtained, provided that the concentrations of LPS [LPS d] and citrate [Ci] are not equal[75]: 
(1/([Ci]o−[LPSd]o)*(ln([Ci]/[Ci]o)/ ([LPSd]/[LPSd]o))=kt       (8) 
Yet, the change of detectable [LPSd] is based on the change of activity, which is usually given in 
EU/mL, whereas citrate is given in mol/L. In order to convert EU/mL in mol/L it is assumed that 1 
EU correlates approximately to 10-10 g (100 pico gram) LPS from E.coli[76], [77]. With a molar 
mass of approximately  10000 g/mol for LPS, 100 EU/mL are equivalent approximately to 10-9 
mol/L[78], [79]. As a consequence, 10-3 mol/L citrate is in a substantial molar excess compared to 
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10-9 mol/L of LPS ([C]>>[LPS]). Theoretically, this would already lead to reaction kinetics of pseudo 
first order, because the concentration of citrate will not change significantly during the reaction 
and can therefore be neglected. However, our results (Figure 16) show that the actual citrate 
concentration has indeed a significant effect on the reaction kinetics. Furthermore, the results 
indicate that the kinetics seem to be independent of the LPS concentration, which is reasonable, 
because citrate is in an excess of up to seven orders of magnitude [C]>>[LPS]. A change of the LPS 
concentration, for example by a factor of 1000, will presumably not affect the kinetics, since 
citrate would still be in excess. Keeping this in mind, the starting molar concentration of citrate 
[Ci]o will only be marginally reduced by subtraction of the initial molar concentration of LPS [LPSd]o 
and leading to the following approximation: 
[Ci]o−[LPS]o = [C]o         (9) 
Concomitantly, the marginal consumption of [Ci] due to the low molar concentration of LPS is 
also negligible and allows for the following assumption: 
 [Ci]/[Ci]o = 1          (10) 
With respect to the equations (9) and (10) the equation (8) can be approximated and written as 
follows: 
(1/([Ci]o)*(ln(1/([LPSd]/[LPSd]o))=kt       (11) 
Finally, the equation can be rearranged to give the detectable concentration of LPS [LPSd] as 
function of time, and depending on the citrate concentration: 
[LPSd] = [LPSd]o*exp(-[Ci]kt)        (12) 
The simulation of masking kinetics with different citrate concentrations, using equation 12, 
resulted in a good agreement with the experimental data (Figure 16). Consequently, this model 
reflects very well the observed behavior of the reaction, in which the endotoxin recovery is 
strongly dependent on the citrate concentration. However, specifications may change, if initial 
concentrations of the components are substantially changed or if additional components (e.g. 
salts and proteins) are included in the sample conditions.  
3.2.3.2 Minimum citrate concentration 
Citrate has been identified to control the reaction kinetics of endotoxin masking. To get a deeper 
understanding of the role of citrate, the minimal concentration of citrate required to initiate 
masking at constant polysorbate concentrations was analyzed. The result shows that 
approximately 0.06 mM of citrate is necessary for masking (Figure 17). This concentration is 
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orders of magnitude higher than the molar concentration of LPS, assuming that there is no 
reasonable reaction stoichiometry.  Nevertheless, citrate might destabilize LPS aggregates by 
considering the potential role of citrate during masking. For example, permeabilization (reduction 
of rigidity) of LPS aggregates occurs when ionic interactions between LPS molecules are disturbed. 
Primarily, magnesium as well as calcium cations (M2+) stabilize LPS-LPS interactions by the 
formation of salt bridges[62], [80]–[82]. It has also been shown that complex forming agents can 
permeabilize such structures [83], [84]. In the presence of citrate, complex formation between 
divalent cations and chelator occurs. Thus, it is supposed that citrate competes for divalent 
cations bridging LPS molecules resulting in a permeabilization of LPS aggregates, because of 
complex formation[85]. Corresponding complex formation constants of magnesium or calcium 
citrate are in the range around 0.05 mM[86]–[88]. This might explain the required molar excess 
of citrate compared to LPS for masking, because at lower citrate concentration, the complex 
formation of calcium or magnesium by citrate is not favored and in consequence the LPS-LPS salt 
bridges are not destabilized, which prevents intercalation of surfactants and in turn masking of 
endotoxin.  
3.2.3.3 The role of divalent cations 
As described above, divalent ions play an important role in the stabilization of supramolecular 
LPS structures. Aggregates of LPS possess a certain degree of rigidity, maintained by salt bridges 
between LPS molecules, which in turn affect the susceptibility to masking. To this end, masking 
rate can be inhibited by the supplementary addition of divalent magnesium ions. This explains 
former observation showing that under certain circumstances, endotoxin activity in LAL can be 
maintained through the suppression of aberrant aggregation of endotoxin by saline and 
buffers[89]. It is most likely that the addition of divalent cations neutralizes the complex 
formation capability of chelators and favors the stabilized LPS state, because the state of 
equilibrium is changed, when the sample matrix is changed. Importantly, the retrospective 
addition of divalent ions to samples in which the endotoxin is masked, enabled no recovery of 
endotoxin, but the progress of masking can immediately be stopped (Figure 15B). Thus, the 
effective addition of cations has to take place before endotoxin is already masked. These results 
demonstrate that the destabilization of LPS (Equation 3) can be prevented by the addition of 
divalent ions, but when LPS is already masked, the consecutive reaction step (Equation 4) is not 
affected by supplementary addition of divalent ions. To achieve a reversal of endotoxin masking, 
the merely addition of divalent ions is not sufficient. For such an approach, also surfactants have 
to be neutralized or removed. This approach will be discussed in detail in chapter 3.4 demasking 
endotoxins.  
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3.2.3.4 Control of reaction rate 
In general, to start the reaction of endotoxin masking, a certain energy barrier has to be 
overcome, which controls the reaction rate. Obviously, the reaction rate can be manipulated by 
its energy input. For instance, the reaction kinetics can be accelerated chemically by e.g. 
increasing chelator concentration (3.2) or physically by e.g. increasing incubation temperature of 
a sample (3.1). Moreover, it is conceivable that the degree of the energy barrier depends on the 
endotoxin itself. Endotoxin from different sources may have different molecular structures and 
in turn different masking susceptibilities due to varying stabilization mechanisms of bacterias´ 
outer membrane. In consequence, endotoxins with different stabilizing mechanisms may have 
different energy barriers and result in manipulated reaction kinetics. To this end, the 
heterogeneity of endotoxins and their detectability in LER-affected samples is studied in the next 
chapter (3.3). 
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3.3 Heterogeneity of endotoxins and their detectability in common 
biopharmaceutical formulations 
3.3.1 Introduction 
LPS play an important role in the pathogenesis and manifestation of Gram-negative infections 
and in particular of septic shock. Due to the fact that the structures of LPS can vary significantly 
in its O-antigen, core region and lipid A, not all endotoxins possess the same toxicity[17]. 
However, to control a potential contamination event in drug products by bacterial endotoxins, 
the sensitive and specific detection of LPS is of great importance. BET has been proven to 
effectively detect LPS. These tests are based on reactions between the lipid A of LPS and specific 
enzymes derived from the clotting cascade in horseshoe crabs[33], [90]. For quantitative 
detection of endotoxin, measures of the unknown samples are compared with standard curves. 
Such standard curves are prepared by known and defined standard endotoxins. The primary 
standard in BET is called Reference Standard Endotoxin (RSE), which is endotoxin from E.coli 
O113:H10:K negative. The RSE is purified in several steps including hot phenol-extraction, 
alcoholic precipitation, enzymatic digestion of nucleic acids and intense dialysis[91]. For a better 
handling lactose and polyethylene glycol are added. This standard is worldwide accepted and sets 
the baseline for secondary or tertiary standards. Due to the limited availability of the RSE, vendors 
of BET systems distribute secondary standards called Control Standard Endotoxins (CSE), which 
are calibrated against the RSE. The preparations of these secondary standards are inspired by 
RSE, but the source can differ from E.coli O113 and exact production processes and formulations 
are not published.  
 
After public recognition of the LER phenomenon, many not publicly accessible endotoxin recovery 
studies in biopharmaceutical drug products and their formulations were performed by endotoxin 
test providers, contract labs and pharmaceutical companies. The masking effects have been 
widely confirmed, especially if the tested drug products contain surfactants and chelators. Such 
hold time experiments are usually performed using standardized endotoxins like CSE and RSE as 
spike. However, since bacterial endotoxin tests are commercially used, the source and 
preparations of appropriate standard endotoxins are debated[24]. Especially in the case of LER 
the source of endotoxin can be discussed, again. It is questionable, whether LER is depending on 
the endotoxins used in BET. Obviously, depending on the source, preparation and degree of 
purification, the LPS itself and the accompanying matrix components can vary in a respective 
preparation[11], [92]. For instance, endotoxins from different bacteria can differ in their 
molecular structures. There are differences in the lipid A (e.g. acylation), core region (e.g. 
substation of sugar units) and O-antigen (e.g. distribution of sugar units). Moreover, depending 
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on the preparation endotoxin suspensions may vary in their compositions. For example, crude 
suspension of bacteria, popularly known as Naturally Occurring Endotoxin (NOE), may contain 
substantial amounts of lipids and proteins and phenol-extracted endotoxin preparations may only 
contain limited contents of hydrophobic matrix components. Some experiments have supposed 
that the detectability of selected endotoxins in complex samples might be more robust compared 
to detectability of commercially available standard endotoxins[93], [94]. Therefore, endotoxins 
from different bacteria, grown under manipulated conditions, crude and highly purified 
endotoxins as well as endogenous endotoxins are analyzed with regard to their detectability in a 
polysorbate/citrate matrix in the present study. 
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3.3.2 Results 
In order to study the masking susceptibility of endotoxins from different bacteria, crude 
suspensions of bacterial endotoxin were prepared. To this end, bacteria from E.coli, E.cloacae, 
S.marcescens, P.aeruginosa, B.cepacia, S.maltophilia and R.pickettii were grown under equal and 
defined conditions (2.4.1 preparation 1). After approximately 18 hours of growth, absorbance of 
all bacterial suspensions were determined (Table 3). Bacteria from E.coli and E.cloacae showed 
highest absorbance (> 1.7), whereas S.maltophilia and B.cepacia showed lowest absorbance (< 
0.7). Bacteria from S.marcescense showed a medium absorbance of 1.4.  
Table 3 Growth of different bacteria and release of endotoxin 
Growth of different bacteria and activity of their endotoxins are shown. Bacteria were grown under 
constant conditions and before harvesting, absorbance (600 nm) of the entire bacterial suspension 
were determined (2.4.1 preparation 1). Endotoxin activity was determined in the particular sterile-
filtrated supernatants of bacterial suspensions. 
   
Source 
Absorbance 
[600 nm] 
Activity  
[EU/mL] 
E.coli O55:B5 1.9 146,174 
E.coli O113 1.7 402,789 
E.cloacae  1.7 189,103 
S.marcescens 1.4 116,175 
P.aeruginosa 0.9 8,595 
B.cepacia 0.7 357 
S.maltophilia 0.3 4,557 
R.pickettii 0.8 77,815 
 
The absorbance reflects the evolved biomass and in turn is an indicator for growth of the 
particular bacteria under given conditions. This result clearly indicates varying growth 
characteristics of different bacteria under given conditions. Endotoxins are usually incorporated 
in the bacterial cell wall, but during growth, substantial amounts of endotoxin are released into 
the environment of the bacteria. Therefore, the endotoxin activity in the supernatant is of great 
interest. Interestingly, the detectable endotoxin activities of the different bacterial supernatants 
ranged from approximately 400 to 400,000 EU/mL. Between the generated biomass of cells and 
the detectable activity only a weak correlation is given.  
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Figure 18 SDS-PAGE of crude bacterial endotoxin preparations from different bacteria 
Silver-stained SDS-PAGE of sterile filtrated supernatants of bacterial suspensions (2.4.1 preparation 1) 
is shown. The lanes reflect endotoxins from E.coli O55:B5 (1), E.coli O113 (2), E.cloacae (3), 
S.marcescens (4), P. aeruginosa (5), B.cepacia (6), S. maltophilia (7) and R.pickettii (8). 
Furthermore, these bacterial supernatants were applied to SDS-PAGE and silver stained (Figure 
18). The typical ladder pattern of LPS can be observed at most lanes and the limited intensities of 
the bands reflect low concentrations, which are approximately in agreement with the detected 
activities (Table 3). Upon closer examination, also variations in the arrangement of bands 
between the different endotoxin samples can be observed, which reflect different molecular 
structures and proof heterogeneity of endotoxins. To study the masking susceptibilities of crude 
endotoxin preparations, these preparations were used as endotoxin source for recovery 
experiments in polysorbate/citrate matrices (Table 4). The crude extracts of endotoxins from 
E.coli, E.cloacae and S.maltophilia resulted in low recovery already at day 0. Endotoxins from 
S.marcescens, P.aeruginosa, and R.pickettii showed a gradual loss of recovery over time. The 
endotoxins from B.cepacia could be detected over time and showed no trend in reduced activity. 
This result clearly indicates that endotoxins from different bacteria, but grown and prepared 
under equivalent conditions exhibit different masking susceptibilities.  
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Table 4 Endotoxin recovery of different endotoxins 
Recovery of endotoxin from different species over time is shown. Sterile filtrated bacterial supernatants 
(2.4.1 preparation 1) were diluted to approximately 50 EU/mL in depyrogenated water (positive 
control). For recovery experiments the endotoxins were spiked with 0.05 wt % polysorbate 20 and 10 
mM sodium citrate (reverse mode, 2.5.3.2). Endotoxin recovery was determined after 0, 1, 2, 5 and 7 
days of incubation at RT. 
  
Recovery (%) 
Source positive  
control 
T0 T1 T2 T5 T7 
E.coli O55:B5 40.9 32 7 8 2 0 
E.coli O113 64.7 42 0 0 0 0 
E.cloacae  50.9 20 4 1 0 0 
S.marcescens 60.5 106 46 29 12 8 
P.aeruginosa 79.6 135 29 25 23 16 
B.cepacia 48.5 248 81 141 92 113 
S.maltophilia 37.9 20 1 1 0 0 
R.pickettii  68.4 108 73 80 71 55 
 
Furthermore, crude endotoxin extracts from E.coli O113, P.aeruginosa and B.cepacia were 
prepared under different growth conditions (2.4.2 preparation 2). Thereby, the bacteria were 
grown under conditions including rich-nutrition media (100 % LB) and elevated temperatures (37 
°C) as well as low-nutrition (1 % LB) and ambient temperatures (RT).  
 
Figure 19 Comparison of crude endotoxin preparations from different bacteria 
Endotoxin recovery is plotted as function of incubation time. 100 EU/mL endotoxin from different 
bacteria ((A) E.coli O113:H21-, (B) B.cepacia and (C) P.aeruginosa) were spiked into samples containing 
10 mM sodium citrate and 0.05 wt % polysorbate 20 and incubated at RT (reverse mode, 2.5.3.2). The 
used endotoxin extracts were derived from two different bacterial growth conditions (2.4.2 preparation 
2). Squares reflect recovery of endotoxin from bacteria grown at 37 °C using 100% LB media. Triangles 
reflect recovery of endotoxin from bacteria grown at room temperature using 1% (v/v) LB media. Each 
endotoxin was prepared in triplicate. The corresponding endotoxin measurements of three repetitions 
were analyzed on the same microtiter plate and for calculation of the data points the mean value of 
the three individual preparations were used. The error bars represent the standard deviation of the 
three replicates. 
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Endotoxin from E.coli O113 is not recovered independent of the growth conditions of the bacteria 
(Figure 19A) after one day of incubation. In contrast, the recovery of endotoxin prepared from 
B.capecia shows no significant decline, regardless of the different growth conditions (Figure 19B). 
Interestingly, recovery of endotoxin from P.aeruginosa depends on different growth conditions 
(Figure 19C). In this case, modified growth conditions resulted in diverging masking kinetics. To 
this end, it has been described that bacterial growth under limitation of divalent cations may also 
affect the molecular structures of endotoxin[95]. To further study this effect, bacteria from 
E.cloacae were grown under rich nutrition conditions in the presence (EDTA) and absence (TRIS) 
of the strong complex forming agent EDTA (2.4.2 preparation 2). The endotoxin recovery kinetics 
indicates that both endotoxins are affected by masking over time (Figure 20). However, the 
recovery over time of endotoxin, which was prepared out of EDTA-treated bacterial cells (Figure 
20B) is greater than the recovery of endotoxin from bacteria which was not treated with EDTA 
during bacterial growth (Figure 20A). Comparing the error bars in both experiments, endotoxin 
recovery from EDTA treated cells tend to be more variable and by chance, a trend to reduced 
recovery over time is not observed. Although chelators have crucial effects on masking of 
endotoxin, the presence of chelators during bacterial growth reduces the masking susceptibility 
of the endotoxin under given conditions.  
 
Figure 20 Endotoxin recovery kinetics of endotoxin from E.cloacae 
Endotoxin recovery is plotted as a function of incubation time. 100 EU/mL endotoxin were spiked into 
samples containing 10 mM sodium citrate and 0.05 wt % polysorbate 20 and incubated up to seven 
days at 4°C. The crude endotoxin extracts were derived from E.cloacae and the media (100% LB) for 
bacterial growth at 37 °C was supplemented with (A) tris buffer and (B) EDTA (2.4.2 preparation 2). Each 
data point represents the mean of three independent measurements. The slope is obtained by linear 
fit of the mean data points. The error bars represent the lowest and highest determined values at each 
time point. 
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However, for investigation of endotoxin masking in quality control of pharmaceutical industries 
standardized endotoxins are requested by regulatory authorities (US FDA). Such standard 
endotoxins are prepared by hot-phenol extraction of LPS [91]. Thereby, hydrophobic components 
like phospholipids and lipoproteins are removed. To analyze, if masking susceptibilities of 
endotoxin are affected by purification, phenol extracted endotoxins from E.coli, S.marcescens and 
P.mirabilis were spiked into samples containing a chelator and surfactant and detected over time 
(Figure 21). In this case, endotoxin from E.coli was low (14%) in recovery directly after spiking and 
no activity of endotoxin was detectable after one day of incubation. The endotoxin from 
S.marcescens was detectable (90%) at day 0, but likewise low (21%) after one day of incubation. 
Although endotoxin from P.mirabilis decreases over time, significant amounts of endotoxin were 
recovered (>43%) at all time points. These results show different masking susceptibilities of the 
studied endotoxins, indicating that phenol extraction is not eliminating the heterogeneity of 
endotoxins from different bacteria.  
 
Figure 21 Comparison of phenol-extracted endotoxins from different bacteria 
Endotoxin recovery is shown over incubation time. 100 EU/mL of three different endotoxins were 
spiked into samples containing 10 mM sodium citrate and 0.05 wt % polysorbate 20 and incubated up 
to 4 days at RT. The used endotoxins were phenol-extracted clinical isolates. The black bars reflect 
endotoxins from E.coli, grey bars reflect P.mirabilis and white bars reflect S.marcescens. 
 
To further evaluate the impact of endotoxin purification, endotoxins from the same bacterial 
species (E.coli O55:B5), but prepared by different methods were analyzed. Phenol-extracted 
endotoxin and crude supernatants of bacterial suspension were spiked into a polysorbate/citrate 
matrix and incubated up to six days at room temperature (Figure 22A). Both preparations show 
no recovery after one day of incubation, which confirms the pronounced masking susceptibility 
of endotoxin from E.coli. Due to the fast kinetics of masking, the experiment was also performed 
at decreased incubation temperature (4 °C) (Figure 22B). The reduced incubation temperature 
was chosen, because endotoxin masking can be decelerated, allowing a better resolution of slight 
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differences in masking susceptibilities (3.1). After 2 days of incubation 50% and after 14 days 14% 
of the initial endotoxin content can be detected within the crude extract. In comparison, the 
recovery of phenol-extracted endotoxin was low after one day of incubation (27%) and no 
significant content of endotoxin was detectable after three days of incubation. Under these 
circumstances the detectability of crude endotoxin preparations decreases slower compared to 
phenol-extracted endotoxin. However, both preparations of endotoxin are affected by masking. 
In consequence, endotoxin masking kinetics can be affected by the extraction method of 
endotoxin, but the kinetics rather depends on the source of bacteria. 
 
Figure 22 Endotoxin recovery kinetics of different endotoxin preparations 
Recovery of endotoxin from E.coli O55:B5 is shown over incubation time. 100 EU/mL of gel-filtrated 
endotoxin (black bars) and sterile filtrated bacterial suspension (grey bars) were spiked into samples 
containing 10 mM sodium citrate and 0.05 wt % polysorbate 20. The samples were incubated up to 14 
days at (A) RT and (B) 4°C. 
In all of the examples above, the source of endotoxin was known and the endotoxin was 
consciously added to samples containing surfactants and chelators. In order to examine a real 
endotoxin contamination, the detectability of an endogenous contaminated monoclonal 
antibody was analyzed. Therefore, a lyophilized antibody was solubilized in four different buffer 
systems and an average endotoxin activity of 135 EU/mL and 114 EU/mL was determined before 
and after sterile filtration, respectively (Table 5a). The different buffer systems as well as the 
filtration had no major effects on the detectability of the endogenous endotoxin contamination 
of the antibody.  
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Table 5 Detection of an endogenous endotoxin contamination 
Activity of an unknown endotoxin contamination under different buffer conditions is shown. 10 mg/mL 
monoclonal antibody (MAK33) were solubilized in A) 25 mM sodium citrate, pH 6.5; B) 10 mM sodium 
citrate, pH 7.5; C) 160 mM trehalose, 50 mM sodium phosphate pH 6.2 and D) 10 mM sodium 
phosphate, pH 7.5).  a) Endotoxin content was determined before and after sterile filtration (0.2 µm). 
For endotoxin detection EndoZyme® was used. b) After filtration 0.07 and 0.05 wt % polysorbate 80 
were added to the samples 1.1 and 2.1, respectively. 0.04 and 0.05 wt % polysorbate 20 were added to 
the samples 3.1 and 4.1, respectively. Endotoxin activity was determined immediately after addition of 
polysorbate (day 0) and after incubation of three days (day 3) at RT. For endotoxin detection EndoLISA® 
was used. 
a  before filtration after filtration 
# Sample: 
Activity 
[EU/mL] 
Activity 
[EU/mL] 
1.1 MAK + Buffer A  116.9 109.0 
2.1 MAK + Buffer B 140.1 118.3 
3.1 MAK + Buffer C 128.7 93.5 
4.1 MAK + Buffer D 152.8 136.2 
 Average 134.6 114.3 
 
Known from previous studies, the simultaneous presence of polysorbate and a chelator like 
citrate can mask the endotoxin (3.1 and 3.2). Therefore, polysorbate was added to the antibody 
solution. Immediately after addition of polysorbate, the endotoxin content was determined and 
comparable contents of endotoxin were detected. However, when the antibody was incubated 
for three days at room temperature, the detectable amount of endotoxin significantly decreased 
in all of the examined samples (Table 5b). This clearly demonstrates that an endogenous 
endotoxin contamination, which reflects a real naturally occurring endotoxin, may be masked in 
common formulation matrices. 
 
 
b  day 0 day 3 
# 
Sample: 
Activity 
[EU/mL] 
Activity 
[EU/mL] 
1.2 MAK + Buffer A + Polysorbate 80 98.5 2.8 
2.2 MAK + Buffer B + Polysorbate 80 95.6 2.1 
3.2 MAK + Buffer C + Polysorabte 20 117.9 5.3 
4.2 MAK + Buffer D + Polysorbate 20 131.7 6.8 
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3.3.3 Discussion 
In previous studies (3.1 and 3.2), the phenomenon of LER has been studied, using standardized 
endotoxins from E.coli. For analytical applications, standards are indispensable to determine 
unknown concentrations and to validate a detection method. However, to investigate if the 
phenomenon of LER is limited to the use of standardized endotoxins from E.coli, detectability of 
endotoxins from different sources was studied in a typical biopharmaceutical drug product matrix 
containing polysorbate and sodium citrate. Phenol-extracted endotoxins (Figure 21), crude 
endotoxin extracts (Table 4, Figure 19 and 20) and endogenous endotoxin (Table 5) were 
incubated into samples containing polysorbate/citrate. These results show that LER is not limited 
to standardized endotoxins from E.coli. Endotoxins from different sources and alternative 
preparations of endotoxin can be affected as well as standard endotoxin preparations by LER. 
Basically, these results clearly demonstrate different masking susceptibilities of different 
endotoxins. LPS reflect a complex group of molecules, which possess a common general 
architecture[11] and due to the amphoteric and amphiphilic nature of LPS supramolecular 
structures are formed[17], [70]. In the case of masking, it is supposed that the presence of 
complex forming agents destabilize the salt bridges of divalent cations between LPS, leading to a 
reduced rigidity of the aggregate. The additional presence of a surfactant may then change the 
initial supramolecular structure and promote the formation of mixed aggregates, thus limiting 
the detection of endotoxin. Taking this assumption into account, differences in the molecular 
structure of LPS may explain the diverging masking susceptibilities of endotoxins from different 
sources.  
3.3.3.1 Molecular heterogeneity of LPS 
In general, LPS are very heterogeneous molecules. Already the application of a single source LPS 
on a SDS-PAGE results in a ladder of bands (Figure 18). This reflects the nature and number of 
sugars within a unit, the nature of the linkages of the sugars as well as the number of repetitive 
units. O-antigen sugars appear to be most variable, core structures appear to be less variable and 
in turn Lipid A structures are considered as the most conserved part of LPS within a genus.[9], 
[96], [97] With regard to the previously described studies on endotoxin masking, it has been 
demonstrated that destabilization of the LPS aggregates is the crucial step in masking (3.2). Due 
to the fact that the O-antigen only marginally contributes to the ionic stabilization, the 
heterogeneity of the O-antigen will be neglected in the following examination. Although lipid A 
and core region are supposed to be the most conserved part of LPS, diverse molecular structures 
of LPS have been observed[11], [23], [98]. Relevant modifications are expected within the charged 
substitutes (e.g. phosphates, amines) as well as acylation (e.g. number, length, saturation) in the 
core region and lipid A of LPS. 
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In consequence, LPS from different bacteria may exhibit different molecular structures and 
therefore, equivalent prepared endotoxins (phenol-extracted) from different bacteria are 
expected to show different kinetics in endotoxin recovery studies. For instance, recovery of 
endotoxin from E.coli and S.marcescens is low (< 25 %) already after one day of incubation (Figure 
21). In contrast, the endotoxin from P.mirabilis showed substantial detectability over time. 
Interestingly, the lipid A structures of E.coli and S.marcescens are assumed to be similar[99], 
whereas the proposed molecular structure of lipid A from P.mirabilis exhibits some differences. 
Differences are seen for example in the acylation and the substitution of the ester bound 
phosphate groups linked to the glucomsamine backbone[100]. Thus, modifications in the lipid A 
of P.mirabilis might be a reason for the diverging masking kinetics compared to E.coli and 
S.marcescens. A similar behavior was observed when crude preparations of different endotoxins 
were compared in recovery kinetics (Figure 19, Table 4). The results show endotoxins which are 
rapidly affected by LER (e.g. E.coli O113) and endotoxins which are less susceptible (e.g. 
P.aeruginosa). Endotoxin from B.cepacia was not affected by masking within the given conditions. 
For B.cepacia, it is also described that the LPS possess an unusual structure. The bacteria lower 
the anionic charge of the cell surface by the substitution of 4-amino-4-deoxyarabinose (Ara4N) 
residues bound to phosphates of the lipid A backbone[101], [102]. Interestingly, endotoxins from 
P.mirabilis and B.cepacia are less susceptible to endotoxin masking and both are known for their 
almost stoichiometric substitution of Ara4N[103]. This might explain the limited masking 
susceptibility. 
 
Figure 23 Structural modifications of lipopolysaccharides 
Depending on the environmental conditions during bacterial growth phosphorylation or acylation can 
change the molecular LPS structure. Changed LPS structures can result in different interactions between 
LPS molecules: Ionic interactions between LPS molecules in the presence (A) and absence (B) of divalent 
cations. (modified figure from Yan et al.[95]) 
As described above, chelators destabilize ionic interactions between negative charged LPS 
molecules and divalent cations. Here, if LPS molecules possess additional positively charged 
substituents, like Ara4N, LPS molecules can form ionic interactions without divalent cations to 
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stabilize their supramolecular structures. Under such conditions, LPS structures are independent 
from divalent cations and chelation of divalent cations has no effects on stability of the 
supramolecular structures of LPS (Figure 23). Consequently, the intercalation of surfactants into 
LPS aggregates is limited and the endotoxin is less susceptible to masking under such conditions. 
Moreover, different bacteria need different conditions for an optimal growth. Comparing 
absorbance of bacterial suspensions from different bacteria and the corresponding detectable 
endotoxin activities, huge differences in growth and endotoxin content are observed (Table 3). 
However, bacteria are able to adapt themselves to an unfavorable environment to ensure 
viability. It is known that bacteria are able to modify their primary LPS structure under certain 
growth conditions, in order to reinforce the external membrane to assure best protection against 
the environment[95]. Moreover, bacteria possess the ability to alter or regulate their lipid A form 
under specific environmental conditions[98]. For instance, after growth of bacteria under divalent 
cation limitation (e.g. in the presence of EDTA), their LPS exhibits raised contents of aminoethanol 
and Ara4N (Figure 23)[95]. Therefore, using endotoxin from bacteria grown under divalent cation 
limitation, displays attenuated recovery kinetics (Figure 20), supporting previous assumption. 
However, it has to be pointed out that not all endotoxins are similarly affected, if growth 
conditions are modified. Comparing the recovery kinetics of endotoxin from the same source, but 
grown under different conditions does not automatically result in a change of the masking 
susceptibility (Figure 19). Thus, due to the unknown source of a potential contamination, it is 
impossible to predict the species of bacteria, its modifications due to the growth conditions, its 
molecular structure and consequently its susceptibility to endotoxin masking.  
3.3.3.2 Breakdown products of Gram-negative bacteria 
In case of a bacterial endotoxin contamination event, LPS might be present in diverse assemblies. 
For example, if viable bacterial cells are present, LPS are embedded in the outer membrane of 
the cell to form its outer layer. In addition, LPS can be exposed in so called outer membrane 
vesicles (OMV), which are segregated by intact cells to improve their protection. Furthermore, 
during cell division or cell death monomers and multimers of LPS can be released from the 
bacterial cell. Hence, a set of LPS assemblies (Figure24) can exist in parallel. Noteworthy, the 
composition of such assemblies can be diverse. A mixture of LPS and accompanying molecules 
like lipoproteins, phospholipids are not necessarily evenly distributed. For example, OMV 
frequently contain a high ratio of LPS with extended O-antigens but contain less protein compared 
to the originated bacteria[104]. Depending on a particular contamination event, the whole set of 
assemblies can be present in a sample. This would be the case, if there is an acute bacterial 
contamination event. Otherwise, it is also possible that there are only break down products of 
the bacteria present in a sample. This can be the case if break down products of the bacteria are 
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transferred into a sample or parts of the contamination are already eliminated during handling 
(e.g. chromatography) of the sample.  
 
Figure 24 Origin of LPS – Bacterial cells and their breakdown products 
(A) LPS are the major building block of the outer membrane of Gram-negative bacteria. Break down 
products of the bacteria can be (B) fragments of bacteria, (C) OMVs which are segregated by the cell 
and (D) monomers. 
Considering not only the heterogeneity of LPS, but also accompanying bacterial components (e.g. 
lipids, porins or proteins), a contamination can be very diverse. Keeping this in mind, comparable 
experiments with regard to LER are only possible using defined endotoxins. Reference or control 
standard endotoxins meet such requirements, because these are highly purified suspensions. For 
preparation of such standards, bacterial suspensions from e.g. E.coli pass through a set of 
purification steps in order to meet the ordinary requirements for a qualified standard[4]. During 
such purification steps, accompanying components like lipids or lipoproteins are removed. The 
removed components do not directly contribute to the endotoxic potential, as the Lipid A of LPS 
has been identified responsible for toxicity of Gram-negative bacteria[14], [15]. Moreover, the 
direct comparison of crude and purified endotoxin preparations gave no indication that the 
purification process is responsible for the masking susceptibility of an endotoxin (Figure 22). Only 
at reduced incubation temperatures, which decelerate the process of masking, the crude 
endotoxin preparations show slower masking kinetics than the highly purified endotoxin. It can 
be speculated that the supramolecular structures of the less purified endotoxin are partly 
stabilized by its accompanying membrane molecules, but masking is not prevented. Obviously, 
crude endotoxin preparations showed also diverse masking susceptibilities (Table 4 and Figure 
19) and the recovery of an endogenous contamination was also low over time (Table 5). This 
proves that endotoxin masking is not driven by a certain preparation of endotoxin. It can be rather 
supposed that the molecular structure of LPS determines if an endotoxin is susceptible to masking 
or not. Accompanying molecules other than LPS can modulate the stability against endotoxin 
masking, but they cannot prevent it.  
3.3.3.3 BET and their standard endotoxins 
The different behaviors of endotoxins from different sources raise the question, whether the 
established standard endotoxins from E.coli are still adequate in BET? This question was already 
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discussed in the 1970th, at the time when E.coli O113 was determined as source for reference 
standard endotoxins (RSE)[24]. Finally, endotoxins from E.coli were chosen, because they were 
very well characterized and their toxic effects were studied also in man[28]. The establishment of 
endotoxin standards from other species was and is possible, but a likewise deep characterization 
would be necessary. Purification is also necessary in order to standardize and enable 
comparability of the endotoxin and fulfil the general requirements of a standard. The alternative 
use of crude endotoxin extracts like the supernatant of a bacterial suspension might reflect in 
certain cases a potential contamination more realistic, but it is very difficult to standardize such 
preparations. However, due to the heterogeneity of endotoxins from different sources, it can be 
supposed that there will be no single standard available, which reflects the diverse nature of 
bacterial endotoxins. The origin of LPS is inevitable connected to the bacteria and in turn an 
intrinsic heterogeneity is included. Moreover, it is impossible to predict the source and way of a 
bacterial endotoxin contamination in a sample. As a consequence, the masking susceptibility of a 
potential contamination is unknown. In order to ensure reliable detection of endotoxin the 
masking capability of a sample has to be evaluated. To analyze the masking capability of a sample, 
endotoxin recovery studies have to be performed with endotoxin spikes, which are susceptible 
to masking. The results above have shown that standardized endotoxins from E.coli exhibit a 
pronounced susceptibility to endotoxin masking and represent an appropriate source for 
endotoxin recovery studies. However, an endotoxin spike should reflect the worst case with 
regard to its masking susceptibility. Although standard endotoxins are susceptible to masking in 
the investigated cases, it is not proven that standard endotoxins always reflect a worst case 
situation. With regard to the heterogeneity of endotoxins and the diversity of sample 
compositions a panel of different endotoxins might be the safest way to determine the masking 
capability of a sample and to ensure detectability of a potential contamination. Finally, if a sample 
is identified with the capability of endotoxin masking, a suitable detection method has to be 
developed in order to detect endotoxin and avoid underestimation of a potential contamination. 
Such developments are discussed in the following chapter (3.4). 
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3.4 Demasking of Endotoxin 
3.4.1 Introduction 
Endotoxin is well detectable in aqueous solutions. However, it becomes significantly less active 
(i.e. undetectable) by common detection systems, if it is masked by surfactants and chelators (3.1, 
3.2 and 3.3). This may have various consequences. The endotoxin can lose its activity, meaning 
that potential endotoxin contaminations in a drug product are basically not harmful anymore 
because the endotoxin is masked and pyrogenic reactions are prohibited. For a sustainable 
suppression of pyrogenic reactions, masking must be irreversible. It has to be ensured that the 
endotoxin will not be demasked in-vivo and becomes pyrogenic again. Noteworthy, modified 
endotoxins with significantly reduced pyrogenicity are well known and used as an adjuvant to 
enhance efficacy of vaccination[105]. Due to this fact, it cannot be excluded that the masked 
endotoxin retains its stimulating effects on the innate immune system, even if the endotoxin is 
depyrogenated. Last but not least, the detection of endotoxin in a sample, independent of the 
toxicity of present endotoxins, gives an indication about the quality of the tested sample. Thus, 
existing test procedures have to be optimized to detect masked endotoxin. Due to the widespread 
use of Limulus-based detection methods, a sample-treatment prior to the use of such 
conventional test methods is desired. Importantly, successful demasking of endotoxin strongly 
indicates that endotoxin is not irreversibly deactivated by masking. In consequence, when 
demasking is possible in-vitro, it cannot be excluded that demasking in-vivo is also possible.  
In order to develop a demasking approach, the nature of endotoxin and the driving forces of 
masking need to be understood. Due to the amphiphilic nature of LPS, it tends to aggregate in 
aqueous solutions. The basic cause of aggregation is to lower Gibbs free energy, which is 
depending on the inner energy and entropy of a system. The latter is predominant in such cases 
and driving hydrophobic effects.[18] Thereby, a variety of supramolecular structures can be 
formed, which are obviously depending on the particular conditions (e.g. molecular structure, 
salinity and polarity). In order to get an idea of a potential supramolecular structure of amphiphilic 
molecules, the concept of packing parameter is a helpful tool. Israelachvili introduced a 
dimensionless equation describing the packing parameter S, which in turn is depending on the 
molecular volume of the hydrophobic moiety, the length of the fully extended hydrophobic 
moiety and the cross-sectional areas of the hydrophilic and hydrophobic moiety. Depending on 
the value of such a calculated packing parameter, a particular supramolecular structure of the 
amphiphilic molecule can be deduced[106].  
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Figure 25 Molecular shape of an amphiphilic molecule determines its supramolecular structure 
The molecular relationship of amphiphilic molecules is illustrated in relation to their supramolecular 
structure. Depending on the molecular shape of an amphiphilic molecule (e.g. cone, cylinder and 
inverted cone) a corresponding supramolecular structure is formed (e.g. micellar, bilayers and 
inverted). (Source: [18]) 
Figure 25 gives some examples of supramolecular structures depending on their molecular shape. 
For example, cone shaped amphiphilic molecules, which often contain only a single hydrophobic 
tail tend to form spherical micelles (e.g. polysorbates); truncated or cylinder shaped molecules 
(e.g. phospholipids) often contain two hydrophobic tails and form preferably bilayers; and 
inverted truncated molecules which contain a pronounced hydrophobic portion tend to form 
inverted structures (e.g. LPS).[18] This concept does not fully describe the supramolecular 
behavior of amphiphilic molecules, as further parameters like the fluidity of acyl chains influence 
likewise the aggregation state. However, the concept of packing parameter helps to understand 
the formation of supramolecular structures.  
Several studies have been performed to explore structure-function relationships of LPS with 
regard to its biological activity[9], [11], [18], [23], [107]–[109]. The primary lipid A structure of LPS 
was identified to constitute the endotoxic activity[9]. Moreover, due to the amphiphilic nature of 
LPS the effects of their supramolecular structures were examined concerning the endotoxic 
activity[18], [66], [109]. Brandenburg and co-workers proposed to extend the term “endotoxic 
conformation”, which is used to describe the conformation of a single lipid A molecule required 
for optimal  triggering of biological effects, to “endotoxic supramolecular conformation” which 
denotes the particular organization of lipid A aggregates in physiological fluids causing biological 
active LPS [110]. Obviously, there is a relationship between endotoxicity and the supramolecular 
structure of LPS (Figure 26). Inverted structures possess a higher degree of endotoxicity compared 
to lamellar structures.[18] This might be comprehensible, as the hydrophobic part of LPS tends to 
be more accessible in solution. In the case of lamellar structures, the hydrophobic part (lipid A) is 
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shielded by the sugar units (core region and O-antigen) in solution and is consequently less toxic. 
Taking this knowledge into consideration, demasking can be achieved by changing the sample 
environment affecting the aggregation state of endotoxin. Based on this hypothesis sample 
treatment for demasking are investigated below.  
 
Figure 26 Relationship between supramolecular structures and endotoxicity 
Correlation between supramolecular LPS structure and bioactivity is shown. Depending on the 
molecular structure of LPS and the environmental conditions, LPS form certain supramolecular 
structures. The latter in turns affects the activity of LPS, in which the lamellar structures possess less 
endotoxicity compared to inverted structures. (Source: [18]) 
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3.4.2 Results 
Various sample compositions are capable to mask endotoxin and render it undetectable (3.1, 3.2 
and 3.2). In order to release masked endotoxin out of polysorbate 20 complexes, samples were 
treated with alkyl alcohols (C8 to C18) prior to endotoxin measurements (Figure 27).  
 
Figure 27 Demasking of endotoxin using co-surfactants 
Endotoxin recovery after demasking using different concentrations of alkyl alcohols with various chain 
lengths is shown. 100 EU/mL of endotoxin were spiked into samples containing 10 mM sodium citrate 
and 0.05 wt % polysorbate 20 and incubated at least for 24 hours at RT. For demasking, samples were 
treated using alkyl alcohols with varying chain length from C8 to C18 (1-octanol (green bars), 1-decanol 
(blue bars), 1-dodecanol (black bars), 1-tetradecanol (white bars), 1-hexadecanol (grey bars), 1-
octadecanol (orange bars)). The concentrations of the alcohols ranged from 0.6 to 40.0 mM. For 
detection of endotoxin EndoLISA® was used. 
This result indicates that sample treatment of masked endotoxin using 1-dodecanol and 1-
tetradecanol enable substantial recovery. Highest recovery was obtained using concentrations of 
5 mM 1-dodecanol and 10 mM 1-tetradecanol, respectively. Using alcohols with alkyl chains 
lengths below C12 or above C14 resulted in recovery below 10 %. Thus, the alkyl chain length of 
the alkyl alcohol is crucial for demasking, but it clearly demonstrates that masked endotoxin can 
be rendered detectable again. There is a small range of 1-dodecanol concentrations which 
enabled demasking. In order to improve demasking using 1-dodecanol, 10 mg/mL Bovine Serum 
Albumin (BSA) was added to the particular 1-dodecanol concentration. BSA was chosen due to its 
capability of binding surfactants (Figure 28). Comparing demasking results in presence and 
absence of BSA, a consistent increase in the recovery of endotoxin can be observed in the 
presence of BSA.  
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Figure 28 Demasking of endotoxin using dodecanol and BSA 
Endotoxin recovery after demasking is shown as function of 1-dodecanol concentration. 100 EU/mL of 
endotoxin were spiked into samples containing 10 mM sodium citrate and 0.05 wt % polysorbate 20 
and incubated for at least 24 hours at RT. Black bars reflect sample treatment using only various 
concentrations of 1-dodecanol and white bars reflect sample treatment using various concentrations 
of 1-dodecanol and additional 10 mg/mL BSA. For detection of endotoxin EndoLISA® was used. 
To investigate whether demasking is due to similar alkyl chain lengths (C12) of polysorbate 20 and 
1-dodecanol, endotoxin was also masked in the presence of polysorbate 80, which possesses C18 
alkyl chain and octoxynol 9 which in turn possess a tetramethylbutyl-phenyl group. All of these 
surfactants induce LER in combination with sodium citrate (3.1). Sample treatment with 1-
dodecanol leads to recovery of 29 % out of polysorbate 80. Out of samples containing octoxynol 
9, no demasking effects were achieved. The combination of 1-dodecanol and BSA lead to a full 
recovery out of polysorbate 80, but only to limited recovery out of octoxynol 9 samples (Figure 
29).  
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Figure 29 Demasking of endotoxin out of different sample matrices using dodecanol and BSA 
Endotoxin recovery is shown after demasking as function of 1-dodecanol concentration. 100 EU/mL of 
endotoxin were spiked into samples containing 0.05 wt % (A) polysorbate 80 and (B) octoxynol 9. All 
samples were buffered using 10 mM sodium citrate. The samples were incubated for at least 24 hours 
at RT. For demasking, samples were treated with 1-dodecanol (black bars) as well as with 1-dodecanol 
and 10 mg/mL BSA (white bars).  For detection of endotoxin EndoLISA® was used. 
These results indicate that there is a relationship between the alkyl chains of the masking and 
demasking components, but the combination of 1-dodecanol and BSA enables demasking out of 
polysorbate 20 and 80 masking conditions. Demasking out of octoxynol 9 is less effective, 
indicating that the LPS-octoxynol 9 complex is stabilized under these conditions (Figure 29B). To 
further enhance demasking, additional agents including sodium dodecylsulfate (SDS) and calcium 
dichloride were added to the previously used demasking agents. 
 
Figure 30 Demasking of endotoxin out of octoxynol 9 matrices 
Endotoxin recovery is shown in dependence of various demasking compositions. 100 EU/mL of 
endotoxin were spiked into samples containing 10 mM sodium citrate and 0.05 wt % octoxynol 9 and 
incubated for at least 24 hours at RT. Demasking was performed using the following components: 5 
mM 1-dodecanol (D), 10 mg/mL BSA (B), 100 mM calcium dichloride (C) and 0.1 wt % sodium 
dodecylsulfate (S). In different demasking approaches, combinations of the components were used (D, 
BD, CBSD, CBS and BSD). For detection of Endotoxin EndoLISA® was used. 
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The combination of calcium dichloride, BSA, SDS and 1-dodecanol resulted in a substantial 
recovery of endotoxin out of samples containing octoxynol 9 (Figure 30). Table 6 gives an 
overview of different demasking approaches out of the different surfactant masking conditions. 
These results indicate that the demasking approach including calcium dichloride, BSA, SDS and 1-
dodecanol is suitable for demasking of all examined masking conditions. 
Table 6 Comparison of different demasking approaches 
Endotoxin recovery after demasking out of different masking surfactants using different approaches is 
shown. In each case 100 EU/mL of endotoxin were spiked in samples containing 10 mM sodium citrate 
and 0.05 wt % of the corresponding surfactant (polysorbate 20, polysorbate 80 and octoxynol 9). After 
incubation of at least 24 hours at RT the samples were treated using 5 mM 1-dodecanol (D), 10 mg/mL 
BSA (B), 100 mM calcium dichloride (C) and 0.1 wt % sodium dodecylsulfate (S). In different demasking 
approaches, combinations of the components were used (D, BD and CBSD). For detection of Endotoxin 
EndoLISA® was used. 
 D BD CBSD 
Masking – Surfactant: Recovery [%] 
Polysorbate 20 78 170 141 
Polysorbate 80 28 94 161 
Octoxynol 9 0 23 168 
 
In the experiments shown so far, endotoxin demasking was performed with a commercially 
available, highly purified endotoxin preparation from E. coli 055:B5. According to previous studies 
(3.3), endotoxin from different sources may have different masking susceptibilities, due to 
variances in acyl chain length of the lipid A part of LPS, as well as modifications of side chains[3]. 
Even more, the length of the O-sugar side chains of LPS potentially impacts the demasking 
approach. It cannot be excluded that highly purified endotoxin and crude endotoxin extracts 
(often called “NOE”) behave different in demasking mechanism. To address this issue and to 
exclude the possibility that the demasking approach is specific for the above used LPS from E. coli 
055:B5, endotoxins from different bacteria with different structures and purities were masked in 
sample matrixes containing polysorbate 20/citrate (Table 7a), polysorbate 80/citrate (Table 7b) 
and octoxynol 9/citrate (Table 7c). For subsequent demasking the various approaches using either 
1-dodecanol alone, BSA/1-dodecanol or calcium dichloride/BSA/SDS/1-dodecanol were applied. 
The results clearly show that the ability to successfully demask endotoxin from various masking 
systems is independent of the source and type of endotoxin used. It shows that demasking is a 
general technique applicable to various types of endotoxin from various sources, under a variety 
of masking conditions.  
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Table 7 Demasking of different endotoxins 
Endotoxin recovery before (masking control) and after demasking of endotoxin from different sources 
and types out of 10 mM sodium citrate and 0.05 wt % (a) polysorbate 20, (b) polysorbate 80 and (c) 
octoxynol 9 are shown. Approximately 50 EU/mL of the particular endotoxin were spiked into the 
corresponding sample matrix. The endotoxins were incubated for seven days at RT in the sample matrix. 
For demasking, the samples were treated using 5 mM 1-dodecanol (D), 10 mg/mL BSA (B), 100 mM 
calcium dichloride (C) and 0.1 wt % sodium dodecylsulfate (S). In the particular demasking approaches, 
combinations of the components were used (D, BD and CBSD). For detection of endotoxin EndoLISA® 
was used. 
a)   Polysorbate 20 / sodium citrate 
Endotoxin: Source: 
Masking 
control 
Demasking 
D BD CBSD 
 
 Recovery [%] 
K.pneumonia LMU 0 66 128 212 
M.morganii LMU 0 81 110 120 
Y.enterocolitica LMU 0 63 174 243 
S.marcescens LMU 0 128 168 182 
N.meningitis LMU 0 9 23 38 
A.baumanni LMU 0 0 124 655 
E.cloacae Hyglos 0 55 156 187 
S.enterica Sigma 0 42 63 76 
E.coli K 12 Invivogen 3 78 80 137 
P.aeruginosa Sigma 0 14 5 179 
 
b)     Polysorbate 80 / sodium citrate 
Endotoxin: Source: Masking 
control 
Demasking 
D BD CBSD 
 
 Recovery [%] 
K.pneumonia LMU 10 22 12 162 
M.morganii LMU 6 35 23 48 
Y.enterocolitica LMU 0 13 19 236 
S.marcescens LMU 4 28 20 80 
N.meningitis LMU 0 55 14 161 
A.baumanni LMU 8 0 57 918 
E.cloacae Hyglos 0 2 26 85 
S.enterica Sigma 0 1 11 25 
E.coli K 12 Invivogen 0 21 12 234 
P.aeruginosa Sigma 0 54 17 78 
 
c)   Octoxynol 9 / sodium citrate 
Endotoxin: Source: Masking 
control 
Demasking 
D BD CBSD 
 
 Recovery [%] 
K.pneumonia LMU 0 12 173 353 
M.morganii LMU 15 15 39 99 
Y.enterocolitica LMU 7 22 168 309 
S.marcescens LMU 0 105 199 326 
N.meningitis LMU 0 0 11 42 
A.baumanni LMU 0 7 337 511 
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E.cloacae Hyglos 24 27 74 183 
S.enterica Sigma 1 1 1 90 
E.coli K 12 Invivogen 0 18 10 69 
P.aeruginosa Sigma 2 85 106 176 
 
To this end, demasking has been demonstrated in diverse surfactant/buffer matrices. These 
matrices were chosen, because pharmaceutical industries often have been using such 
components for formulation of APIs like proteins (table 1). Further, antibodies constitute 
frequently formulated pharmaceutical protein products. Hence, the established demasking 
approaches are applied to systems containing surfactant and an antibody buffered in phosphate 
and saline. Polysorbate 20 and 80 were chosen as surfactants (Table 8).  
Table 8 Demasking of endotoxin out of formulated antibody samples 
Endotoxin recovery before and after demasking out of formulated antibody (PAK) samples is shown. 50 
EU/ml of endotoxin were spiked into samples containing water, buffer (10 mM sodium phosphate and 
50 mM sodium chloride), antibody (10 mg/mL polyclonal antibody) and surfactant (0.05 wt % 
polysorbate 20 and polysorbate 80). Samples were incubated for three days at RT. For demasking, the 
sample containing buffer, surfactant and antibody was treated by using calcium dichloride (C), BSA (B), 
sodium dodecylsulfate (S) and dodecanol (D). For detection of endotoxin EndoLISA® was used. 
Masking surfactant:     
polysorbate 
20 
polysorbate 
80 
Sample: 
C                               
[mM] 
B
[mg/ml] 
S 
[%] 
 D 
[mM] 
Recovery   
[%] 
water - - - - 100 100 
buffer  - - - - 102 99 
buffer + antibody  - - - - 31 44 
buffer + surfactant - - - - 0 2 
buffer + surfactant + antibody - - - - 0 9 
buffer + surfactant + antibody - - - 10.0 17 9 
buffer + surfactant + antibody - - - 1.0 20 7 
buffer + surfactant + antibody  - - - 0.1 0 5 
buffer + surfactant + antibody - 10 - 10.0 41 11 
buffer + surfactant + antibody - 10 - 1.0 3 6 
buffer + surfactant + antibody - 10 - 0.1 2 12 
buffer + surfactant + antibody 100 10 0.1 10.0 5 3 
buffer + surfactant + antibody 100 10 0.1 1.0 16 23 
buffer + surfactant + antibody 100 10 0.1 0.1 67 91 
 
The results show that the buffer solution without polysorbate does not mask the endotoxin. 
Buffer solutions containing antibody, but no surfactant, resulted in reduced endotoxin recovery 
suggesting that already the antibody contributes a masking effect. The endotoxin recovery from 
buffer solutions containing polysorbate and antibody are below 10 % when no demasking 
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treatments were performed. Thus, not only the surfactants but also the antibody is capable of 
endotoxin masking. Endotoxin recovery after demasking of such samples, simulating a drug 
product containing endotoxin, surfactant, buffer and antibody are low using 1-dodecanol alone 
(< 10%). Using a combination of BSA and 1-dodecanol allows moderate endotoxin recovery (10 
to 40 %), but a combination of calcium dichloride, BSA, SDS and 1-dodecanol shows a substantial 
endotoxin recovery in the presence of Polysorbate 20 and 80 (> 60 %).  
To show that demasking is not only possible from solutions containing LPS of a known source, a 
commercially available mouse monoclonal antibody for diagnostic purpose was used, which 
contained an “endogenous” LPS contamination from an unknown source (Table 9).  
Table 9 Demasking of unknown endotoxin 
Endotoxin recovery before and after demasking of endotoxin from an unknown source is shown. A 
contaminated monoclonal antibody (MAK 33) was dissolved in a buffer containing 25 mM sodium 
citrate (pH 6.5) and 150 mM sodium chloride.  Directly after solubilization of the antibody, an endotoxin 
content of 11 EU/mg was determined. Endotoxin masking was initiated by addition of 0.07 wt % of 
polysorbate 80 and incubated for three days at RT. For demasking, the sample containing buffer, 
polysorbate and antibody was treated by using the indicated concentrations of calcium dichloride (C), 
BSA (B), sodium dodecylsulfate (S) and dodecanol (D). For detection of endotoxin EndoLISA® was used. 
Sample: 
C 
[mM] 
B           
[mg/ml] 
S 
[%] 
D 
[mM] 
Recovery               
[%] 
buffer + antibody (0 days) - - - - 100 
buffer + antibody (3 days) - - - - 57 
buffer + polysorbate 80 - - - - 0 
buffer + polysorbate 80 + antibody - - - - 3 
buffer + polysorbate 80 + antibody - - - 10 45 
buffer + polysorbate 80 + antibody - 10 - 10 68 
buffer + polysorbate 80 + antibody 100 10 0.1 0.1 178 
 
This antibody was dissolved in a buffer composition corresponding to the formulation of the 
known antibody drug product Rituximab containing sodium citrate, sodium chloride and 
polysorbate 80 (MabThera®, Rituxan®). The buffer solution containing antibody without 
polysorbate masks approximately 40 % of the endotoxin contamination within 3 days of 
incubation at room temperature. Incubation in buffer containing either polysorbate 80 or 
antibody and polysorbate 80, results in endotoxin recovery below 4%. This shows that an 
endogenous endotoxin contamination can be masked and that the risk of masking applies not 
only for purified or crude endotoxin extracts, but also for endogenous endotoxin. Demasking of 
this endotoxin contamination out of the antibody/surfactant sample resulted in an endotoxin 
recovery of 45 % using 1-dodecanol, 68 % using a combination of BSA and 1-dodecanol and 179 
% using a combination of calcium dichloride, BSA, SDS and 1-dodecanol. This demonstrates that 
the developed approaches are able to demask endotoxin under conditions of relevance for the 
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pharmaceutical industry.For detection of demasked endotoxin, the EndoLISA assay was used in 
all experiments shown above. EndoLISA is the method of choice due to its heterogeneous test 
format, which reduces test interferences substantially[42]. However, in order to investigate if 
other test formats and methods are also applicable after demasking, a recombinant Factor C test 
(homogeneous format) as well as a kinetic chromogenic LAL assay was used for detection of 
demasked endotoxin. Endotoxin recovery before and after demasking was analyzed out of 
polysorbate 20 and 80 in phosphate-buffered saline (PBS) (Table 10). The masking controls 
showed no endotoxin recovery in either sample. However, after demasking substantial contents 
of endotoxin were recovered in all samples using LAL as well as rFC test methods. This experiment 
proves that the detection of demasked endotoxin is independent from the detection system used. 
LAL and rFC are suitable test methods after demasking. 
Table 10 Comparison of different detection methods after demasking of endotoxin 
Endotoxin recovery out of PBS containing 0.05 wt % polysorbate 20 (P20) and polysorbate 80 (P80) is 
shown, respectively. For masking, approximately 10 EU/mL endotoxin were spiked into the samples and 
incubated for three days at room temperature. Afterwards, the samples were treated using 200 mM 
sodium citrate, 100 mM calcium dichloride, 1 mg/mL BSA, 0.1 wt % sodium dodecylsulfate and 0.1 mM 
1-dodecanol. For detection of endotoxin rFC (EndoZyme®) and LAL (Kinetic-QCLTM) assays were used. 
  Recombinant Factor C Limulus Amebocyte Lystate 
Sample: PBS + P80 PBS + P20 PBS + P80 PBS + P20 
  [EU/mL] 
Positive control 9 7 12 7 
  Recovery [%] 
Before demasking 0 0 3 0 
After demasking 65 66 96 47 
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3.4.3 Discussion 
3.4.3.1 Concept of Demasking 
Endotoxin masking by surfactants is currently the most prominent masking cause in quality 
control of biopharmaceutical drug product manufacturing. During masking, the aggregation state 
of LPS is changed, leading to LPS disaggregation and embedment of LPS in surfactant micelles and 
in turn the endotoxin becomes undetectable. Considering the molecular shapes of surfactants 
like polysorbates (cone shape) and LPS (cylindrical / inverted truncated cone shape), mixed 
aggregates result most likely in micellar structures (Figure 31), given that surfactants are in molar 
excess. In the case of a potential contamination event, the commonly used surfactants in drug 
products are in a great molar excess compared to expected LPS concentrations (3.2). 
 
Figure 31 Potential effects on supramolecular structures: Mixing polysorbate and LPS 
Formation of mixed polysorbate-LPS aggregates is shown. (A) Polysorbates possess cone shaped 
structures and form spherical supramolecular structures. (B) LPS possess cylindrical as well inverted 
truncated cone shaped structures and form bilayers and inverted supramolecular structures. (C) Mixing 
polysorbates and LPS, the formation of mixed micelles is predicted, under condition that polysorbates 
are in molar excess. 
To detect masked LPS, LPS have to be liberated from their masking complex. Therefore, it was 
searched for molecules, which are capable to destabilize the LPS-surfactant complex and in turn 
enable a reassembly of LPS. It is hypothesized that a reorganization of LPS is possible, when 
surfactants and LPS do not favor the spherical micellar aggregation state. Concurrently, the 
surfactant LPS complex is unfavored and LPS are released and reassembled. Noteworthy, the pure 
sample dilution below the critical micelle concentration (CMC) of surfactants was not sufficient 
(3.1), assuming that mixtures of LPS and surfactants form stable aggregates. Therefore, the 
application of co-surfactants was considered, because the co-surfactants are capable in affecting 
the supramolecular arrangement of surfactants (Figure 32).  
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Figure 32 Mixing surfactants and co-surfactants 
The change of supramolecular structures is shown when surfactants and co-surfactants are mixed. (A) 
Cone shaped surfactants (e.g. polysorbate) form spherical micelles above critical micelle concentrations 
(CMC). (B) Addition of co-surfactant (e.g. dodecanol) to surfactants. (C) Mixing of surfactants and co-
surfactants results in alteration of supramolecular structures. The overall hydrophobic portion 
increases, whereby the hydrophilic portion remains constant. As a result, potentially cylindrical micelles 
or even bilayers are formed. 
Typically, co-surfactants are not able to form micelles because their solubility in water is lower 
than their critical micelle concentration[111]. But co-surfactants can intercalate into surfactant 
micelles and swell them[112]. Moreover, co-surfactants like long chained alkyl alcohols can 
change the overall packing of aggregates and lead to altered aggregation states[113]. In the event 
of demasking it is expected that co-surfactants intercalate into both surfactant micelles and mixed 
LPS-surfactant micelles. This disturbs the aggregation states of pure and mixed micelles and new 
aggregation states are established. It is probable that the surfactants in presence of co-
surfactants no longer prefer the formation of spherical micelles, but rather prefer the formation 
of cylindrical and bilayered aggregates. This reorganization may in turn enable the release of LPS 
out of masking complex (mixed LPS-surfactant micelles). Moreover, co-surfactants are also 
capable to interact with the fatty acids of LPS, which can affect the aggregation state of LPS. It is 
supposed that co-surfactants support the reaggregation of LPS and “catalyze” the formation of 
inverted truncated cone shaped LPS, which in turn favors the assembly of inverted cubic or 
hexagonal supramolecular LPS structures (Figure 33). This is the working hypothesis of demasking 
and the application of this concept will be discussed below (3.4.3.2). 
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Figure 33 Potential effects on supramolecular structures: Reassembly of LPS 
Potential reassembly of LPS is shown. (A) Mixed LPS-polysorbate aggregates form spherical or 
cylindrical micelles. The addition of a demasking agent (e.g. co-surfactant) changes the overall packing 
of aggregates and leads to segregation of surfactants and LPS. (B) Surfactants form cylindrical micelles 
or bilayers, which no longer stabilize monomeric LPS embedded in micelles. (C) LPS forms preferably 
hexagonal inverted structures which are well detectable. 
3.4.3.2 Realization of demasking concept 
According to the above described concept (3.4.3.1), co-surfactants were studied in order to 
demask endotoxin. To this end, long-chained alkyl alcohols were used for endotoxin demasking 
out of polysorbate 20/citrate samples (Figure 27)[114]. Using alcohols with chain length of C12 
resulted in full recovery of endotoxin. The use of C14 alcohols also resulted in a substantial 
endotoxin recovery, whereas the use of alcohols with longer or shorter alkyl chains was not 
suitable. The beneficial effects of C12 alkyl alcohol might be explained by its chain length, which 
fits well to the alkyl chain length of polysorbate 20. Using the C12 alkyl alcohol for demasking out 
of a matrix, containing polysorbate 80 (Figure 29Aa), the demasking efficiency is lower. In this 
case, the C12 alkyl chain of the alcohol can interact with the C18 of polysorbate as well, but it 
possesses a relatively shorter hydrophobic proportion. However, the principle of swelling micelles 
is still given. The use of alcohols with longer alkyl chains than C12 or C14 would have been 
beneficial for demasking out of polysorbate 80, but was difficult in handling due to their limited 
solubility in water. The working solutions of the alkyl alcohols were already solubilized in ethanol 
to enhance solubility in aqueous solutions. Nevertheless, by adding the working solutions (alkyl 
chain length > C14) to the particular aqueous samples, the ethanol content is likewise diluted and 
phase separation occurs. Under such conditions the endotoxin measurement is not necessarily 
reliable. It is also not possible to increase the ethanol content in the sample to be tested to 
provide better solubility of the long chained alcohols, because of subsequent interference of 
ethanol with the enzymatic reaction of the endotoxin assay.  
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Due to the limited applicability of co-surfactants with alkyls chain lengths above C14, the 
demasking efficiency out of polysorbate 80 was increased by addition of an ancillary component 
capable of binding surfactants. It is supposed that the demasking efficiency of 1-dodecanol is 
extended, by limiting the concentration of “free” surfactants in solution. To this end, BSA was 
chosen, because it is widely available, well characterized and known to adsorb polysorbates[115], 
[116]. The use of 1-dodecanol in combination with BSA resulted in significant enhancement of 
endotoxin demasking out of samples in which polysorbate caused endotoxin masking (Figures 28 
and 29A). However, in the case of octoxynol 9 masking, using BSA and 1-dodecanol for demasking 
was not sufficient. This observation suggests that the masking LPS-octoxynol 9 complex is more 
stable than the LPS-polysorbate complex and 1-dodecanol is less effective in this case. Comparing 
polysorbates and octoxynol 9, dissimilarities in their nature are given. Polysorbates comprise of 
sorbitan substituted with approximately 20 repeat units of polyethylene glycol and an 
unbranched alkyl chain. Octoxynol 9 comprises of approximately 10 repeat units of polyethylene 
glycol and phenyl with a branched alkyl chain (Figure 34).  
 
Figure 34 Molecular structures of surfactants 
Chemical structures of (A) polysorbate 20, (B) polysorbate 80 and (C) octoxynol 9 are displayed. 
Polysorbates contain approximately 20 repeat units of ethylenglycol (=w+x+y+z), which are distributed 
across four chains. Polysorbate 20 possess a saturated alkyl chain of 12 C-atoms and polysorbate 80 
possess an unsaturated alkyl chain of 18 C-atoms. Octoxynol contains 9-10 repeat units of ethylenglycol 
(=n), which are connected to a tetramethylbutylphenyl group. (source: [117]–[119]) 
Comparing hydrophilic hydrophobic balances (HLB) of these surfactants, octoxynol 9 (HLB 13.5) 
is more hydrophobic than polysorbate 80 (HLB 15.0) and polysorbate 20 (HLB 16.7)[120]. 
Furthermore, octoxynol 9 micelles are described to be more asymmetric than polysorbate 
micelles and bind less water than those composed of polysorbate[121]. Hence, it is conceivable 
that octoxynol 9 forms more stable aggregates with LPS compared to polysorbates due to its more 
pronounced hydrophobic nature. In order to destabilize the LPS-octoxynol 9 complex, it was 
searched for a well characterized charged surfactant, because these are harsher than non-ionic 
surfactants[122]. To this end, SDS was chosen, because of its anionic nature, which does not favor 
ionic interactions with LPS and has the capability to mix very well with octoxynol 9[123]. 
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Moreover, SDS has a high affinity to bind to proteins[124]. This effect may also be beneficial for 
displacing LPS adsorbed to BSA and further proteins like antibodies. Taking these considerations 
into account, a combination of SDS, BSA and 1-dodecanol was used for demasking. However, the 
full content of endotoxin could not be retrieved, so that further optimization was needed. It was 
supposed that the masking complex is still too rigid under given conditions. It has been described 
that an increase of ionic strength in octoxynol 9/SDS mixtures can significantly change the 
aggregation state[125]. Especially in the presence of calcium dichloride, SDS aggregates are 
swollen and progress from prolate ellipsoids to extended cylinders or rods[126]. Furthermore, 
divalent cations stabilize LPS aggregates, which may also support the reassembly of LPS and 
neutralize chelators. Using the combination of calcium dichloride, BSA, SDS and 1-dodecanol 
(CBSD) for demasking, endotoxin was successfully detected, when it was masked in the presence 
of octoxynol 9 (Figure 30). These results show that depending on the masking condition different 
approaches are necessary to demask endotoxin. Interestingly, the most complex approach (CBSD) 
was also suitable for demasking out of polysorbates and octoxynol.  
3.4.3.3 Demasking of endotoxins from different sources 
To challenge the described demasking approach, endotoxins from diverse sources were masked 
using different surfactants and treated with different approaches. Summarizing these results, 
sample treatment using CBSD enabled demasking of all endotoxins out of all masking conditions. 
The approach using only 1-dodecanol was expected to be sufficient for demasking out of 
polysorbate 20 (Table 7a). In fact, most of the endotoxins could be adequately recovered, but a 
few endotoxins were limited in recovery. This might be explained by the fact that LPS from 
different bacteria as well as originated from various conditions may possess different molecular 
structures. There are differences in the length and number as well as modifications in linearity 
and saturation of the acyl chains in the lipid A part of LPS. Moreover, variations in the 
composition, decoration and length of the sugar residues in the core region and O-antigen are 
given[3], [98]. These molecular modifications can have effects on the nature and assembly of LPS. 
As assumed before, endotoxin masking is driven by hydrophobic effects, and formation of mixed 
aggregates with additional amphiphilic molecules. Thus, the stability of a LPS masking complex is 
not necessarily only depending on the masking components, but also on the molecular structure 
of LPS. Consequently, to demask some of the endotoxins (e.g. Acinetobacter baumanni), the more 
complex and harsh approach (CBSD instead of D) was necessary for full recovery of endotoxin. 
Moreover, it can be noticed that the detected activity is sometimes partly enhanced compared 
to the detected activity in pure water of the particular endotoxin (Table 7). Basically, the 
molecular structure of endotoxin defines the potential activity of endotoxin[11], but the 
formation of a certain supramolecular structure modulates the detectable activity[18], which is 
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also depending on the environmental conditions[127]. Thus, inverted structures are more active 
than lamellar structures[16], [18]. This is comprehensible, because the activity depends on the 
interaction of a receptor (e.g. Factor C) and lipid A of LPS, which in turn is better accessible by 
inverted than by regular supramolecular structures. For this reason, it is also possible that LPS in 
water possess not exactly the same supramolecular structure compared to LPS after demasking, 
resulting in a diverging detectable activity. However, the overall results in recovery of different 
endotoxins after demasking are in a passable range, considering variabilities in Limulus-based 
detection methods and the heterogeneity of LPS.  
3.4.3.4 Influence of proteins on demasking 
In order to simulate the impact of a protein-based API on demasking, samples containing 
formulated polyclonal and monoclonal antibodies were studied. Also in these cases, the full 
contents of endotoxin could be recovered after demasking. The applied approaches were 
similarly effective as in the absence of a protein during masking. Nevertheless, it is observed that 
a significantly reduced concentration of 1-dodecanol is sufficient for successful demasking in the 
presence of an antibody (table 8). Further demasking studies have also shown that the required 
concentrations of demasking components can vary, depending on the concentration and 
composition of the analyzed sample (data not shown). In consequence, using the discovered 
components for demasking, the required concentrations of demasking components have to be 
adjusted individually. Although there is a good perception of the masking and demasking 
principles, it is difficult to predict the interplay and aggregation state of all sample components 
while endotoxin masking and demasking. Hence, the described molecules used for sample 
preparation represent a toolbox of demasking agents. To develop a dedicated sample preparation 
protocol for demasking endotoxin, broad approaches with various combinations and 
concentrations of all described demasking components are recommended.  
In the case of biopharmaceutical drug products, the API (mainly proteins) is the major component, 
which predetermines the overall sample conditions. Surfactants are added to such protein based 
products to saturate hydrophobic interfaces in order to prevent adsorption and aggregation of 
the API[56]. The results above have been shown that that the phenomenon of LER can be driven 
by the formulation components lacking the API (3.1 and 3.2), but the API can also contribute to 
masking of endotoxin and initiate LER (Table 8 and 9). In contrast, BSA has been shown being 
beneficial during demasking. To this end, depending on the composition and aggregation state of 
sample compositions, more or less surfactants can be adsorbed by a protein[116] and 
noteworthy, proteins are also capable in adsorbing LPS[47]. Thus, the presence of a protein can 
enhance or reduce the endotoxin masking capability of a sample. It is assumed that the “free” 
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concentration and aggregation state of surfactants in a sample can be affected by the API, which 
in turn can influence masking and demasking of endotoxins.  
3.4.3.5 Endotoxin demasking – rearrangement of endotoxin aggregates 
In summary, depending on the particular sample conditions a combination of 1-dodecanol, SDS, 
BSA and calcium dichloride can render the masked endotoxin detectable again. Noteworthy, 1-
dodecanol represents the essential reagent and was present in all demasking approaches. It is 
supposed that 1-dodecanol provides the major driving force in disturbing endotoxin masking 
complexes and supporting the rearrangement of LPS. Figure 35 schematically illustrates 
hypothetical rearrangements of lipid A and polysorbate 20 in the presence of a long-chained alkyl 
alcohol. The illustration emphasizes the pass through several transition states, in which co-
surfactants force swelling of the endotoxin masking complex, followed by forming lamellar 
structures, which in turn enable a reassembly of detectable LPS.  
 
Figure 35 Potential effects on supramolecular structures: Re-arrangements during demasking 
Hypothetical rearrangements of endotoxin during demasking are shown. (A) The lipid A part of LPS is 
embedded in the hydrophobic core of a small sized surfactant micelle. (B) Co-surfactants intercalate 
into the mixed surfactant-LPS micelle and swell it. (C) Intercalation of co-surfactants rearranges the 
micellar structures into lamellar and channel structures. (D) LPS molecules are free to diffuse. (E) 
Surfactants form bilayers and LPS reassembles into detectable structures (e.g. hexagonal inverted). 
In conclusion, the data demonstrate that the detection of endotoxin depends on the particular 
sample conditions. LPS are reversibly deactivated during masking, because LPS can be detected 
again after sample treatment. Concomitantly, it cannot be excluded that demasking also takes 
place in-vivo. Thus, masking of endotoxin is most likely driven by alterations in the supramolecular 
structures of endotoxin, which is controlled by environmental conditions.   
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4 Conclusions 
4.1 Endotoxin demasking – a technical solution 
LER has been observed during quality control of biopharmaceutical drug products using Limulus-
based detection systems[44], [54]. As consequence, the detection of bacterial endotoxins can 
lead to wrong-negative test results. In this work, the detectability of endotoxins in typical 
formulation matrices of biopharmaceutical drug products was analyzed in order to understand 
and overcome LER. The results demonstrate that LER is caused by simultaneous presence of 
surfactants and complex forming buffer agents. The appearance of LER is time and temperature 
dependent and complex forming agents were identified in limiting the reaction kinetics. Variation 
in surfactant and endotoxin concentrations showed no substantial effects on the reaction 
kinetics, but endotoxins from different sources showed effects on the kinetics. Taken together, 
the results above lead to the assumption that LER is caused by alteration of the endotoxin 
aggregation state. Moreover, a two-step masking mechanism is proposed, in which salt bridges 
between LPS molecules are destabilized and subsequently mixed micelles are formed masking 
the endotoxin. In order to render endotoxin detectable again, a sample treatment procedure was 
developed. Thereby, dodecanol was identified very efficient in demasking the endotoxin. The 
presented results clearly demonstrate that demasking is possible out of various formulation 
matrices and independent of the endotoxin source. However, the experiments were based on 
model systems and the conditions of drug products were simulated. The ultimate proof of 
concept is the application in a real drug product which is affected by LER. The cooperation with a 
world´s leading pharmaceutical company enabled the analysis of endotoxin masking in one of 
their biopharmaceutical drug products, which is intended for commercial use. The studied 
product was unequivocally affected by LER (Figure 36A).  
  
Figure 36 Recovery endotoxin before and after demasking out of a drug product 
Endotoxin recovery before and after demasking out of a real life sample is shown. A) Recovery of 10 
EU/mL endotoxin after incubation for 7 days at 4 °C in depyrogenated water (control) and finished drug 
product (DP). B) Recovery of endotoxin out of the drug product after sample treatment. For detection 
a LAL assay was used. The error bars reflect the standard deviation of four individual sample 
preparations (n=4). 
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For demasking the developed toolbox including ionic and amphiphilic demasking agents was used 
and a dedicated sample treatment protocol was established to overcome the LER effect in the 
drug product. Application of the protocol restored the detectability of endotoxin out of the 
affected drug product (Figure 36B). As expected, not all endotoxins show equivalent masking 
susceptibilities. For example, endotoxins from E.coli O55:B5 are less affected than E.coli 
O113:H21 (RSE) and E.cloacae (NOE). However, after sample treatment, all endotoxins were 
detectable in a range between 50 and 200% recovery. Interestingly, the degree of masking had 
no impact on demasking efficiency (Figure 37). This approach enabled for the first time an 
adequate detection of endotoxin over time in this drug product. Consequently, to ensure the 
detection of potential endotoxin contaminations and to reduce the risk of underestimation of an 
endotoxin contamination, the sponsor will use this approach in quality control departments in 
the future to improve patient safety.   
 
Figure 37 Masking and demasking of different endotoxin out of a drug product 
Endotoxin recovery of 2.5 EU/mL of different endotoxins out of a finished drug product after incubation 
for 15 days at 4°C is shown. Endotoxin was measured before (black bars) and after demasking (white 
bars). For detection a LAL assay was used.  
4.2 Perspectives of sample treatments in BET  
The occurrence of LER demonstrates that the requirements for endotoxin testing of modern 
biological drug products are changing. To this end, snapshot measurements of endotoxin will be 
extended by time dependent measurements and trends have to be identified. Moreover, the 
complexity of present and future drug products will not decrease and in consequence, it is 
expected that individual sample preparations prior to the actual test methods will increase. 
Moreover, there are further exciting fields of application, which suffer from inadequate 
endotoxin detection. For example, vaccines can exhibit difficult conditions for BET, because of 
complex sample formulation including aluminum-based nano particles, which are able to adsorb 
endotoxin and strongly interfere with the enzyme reaction in Limulus-based detection systems. 
In such a case, the optimization of given detection methods is of great interest. Another challenge 
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in BET is the group of Advanced Therapy Medical Products, which possess enormously increased 
sample complexity, because such products often contain living cells. However, the ultimate 
challenge of endotoxin testing is the analysis of blood samples, because of pronounced masking 
effects and strong test interference, which substantially reduces sensitivity of the test system. 
Therefore, fast and sensitive detection of endotoxin in blood samples would be a great 
achievement in the field of sepsis diagnosis, which in turn would substantially support decisions 
in the medical treatment of acute infections. Taken together, the presented data contributes to 
a better understanding of endotoxins and helps to improve detection of bacterial endotoxins in 
complex sample matrices.  
4.3 Need for structural analysis of endotoxins in complex sample 
matrices 
Goal of the present work was to establish a technical solution for endotoxin detection in the case 
of endotoxin masking (LER) of biopharmaceutical drug products. To this end, a technical solution 
was developed and a mechanistic model was established, assuming structural rearrangements of 
LPS during masking and demasking. Yet, to confirm the working hypothesis and to further 
improve the current methods, detailed structural analysis of endotoxin will be of interest. It might 
be conceivable to track a change of endotoxin aggregates during masking and demasking with 
physical methods. For instance, it is most likely that the size of aggregates is changed, which could 
be determined using scattering methods like Dynamic Light Scattering (DLS) or microscopy 
methods like Atomic Force Microscopy (AFM). The application of such methods is highly 
appreciated, but there are a few obstacles that need to be overcome. Due to the heterogeneity 
of endotoxin, it exists in a broad variety of aggregates with different shapes and sizes. Thus, the 
analysis of simultaneous alterations of different aggregates will be difficult.  A further challenge 
is the particular endotoxin concentration. Basically, the aggregation state is concentration 
dependent and relevant LPS concentrations are in the pico- to femtomolar range, which 
challenges the detection limit of most analytical methods. Further difficulties are given by the 
molar excess of surfactants compared to LPS. To this end, the detection of structural alterations 
of LPS might be interfered by surfactant aggregates. Due to these difficulties, it might be 
reasonable to start experiments using the above studied polysorbate/citrate matrix as sample, 
but with reduced polysorbate concentrations still allowing for masking, but possibly reducing 
interference. In addition, using rough mutants lacking the O-antigen as endotoxin source could 
be beneficial in such experiments, because a reduced heterogeneity of endotoxin can be 
achieved. Obviously, such conditions do not reflect real conditions in industry, but will support 
the understanding of endotoxin aggregation. This further elucidation of supramolecular 
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alterations can be used in diagnostics for improving endotoxin detection methods, but also 
support fundamental research of stabilities in bacterial membranes.  
4.4 Clinical relevance of masked endotoxin 
Beyond the presented analytical approach, it is also of great interest to further understand the 
clinically effects of masked endotoxin. Endotoxin, when masked could be assumed as 
depyrogenated i.e. the endotoxic activity is neutralized and detection could be assumed as 
dispensable. At a first glance, this is a solid argument, because Limulus-based detection methods 
are useful for identification of LPS and LPS-like structures in samples like biopharmaceutical drug 
products. Comparative studies have shown that activities measured with Limulus-based detection 
methods indicate bacterial contaminations very sensitive. However, it has to be kept in mind that 
Limulus-based detection is derived from an invertebrate crab and is not an in-vivo measure for 
endotoxicity in man. Obviously, to study the real pyrogenicity of masked endotoxin, it must be 
administrated intravenously to man under a variety of conditions (varying concentrations, 
different endotoxin sources, etc.). Yet, such kinds of studies do not correspond with ethic 
guidelines. Alternative test procedures are experiments in animals. In Europe it is difficult to 
perform such studies, because of animal welfare directives of the European Commission. 
Nevertheless, a few unpublished studies using the RPT have been performed, indicating that 
rabbits can positively respond to masked endotoxin, but not imperatively. Using another in-vitro 
method which mimics interaction of endotoxin and Toll-like receptors of the human innate 
immune system might be also beneficial[30]. Interestingly, first results indicate that monocyte 
activation tests (MAT) are also affected by LER. The interaction of masked endotoxin with Toll-
like receptor in the assay seems to be not possible. However, the MAT does not reflect in-vivo 
conditions. It has to be investigated, whether other physiological functions are needed to break 
up the masked endotoxin complex. Otherwise complex formation of endotoxin by chelator and 
surfactant might inhibit immune stimulation via Toll-like receptor immune response. In 
consequence, there is no definite statement available, if masked endotoxin is still hazardous in 
man. Moreover, it has to be considered that masked endotoxin might activate alternative 
immune stimulating pathways. In the field of vaccination, depyrogenated endotoxins are actively 
added to certain drug products to serve as an adjuvant, stimulating the immune system. Such 
effects are desired and support the development of certain adaptive immunity. In contrast, 
biopharmaceutical drug products (e.g. therapeutic proteins), which are focus in the present work, 
can lose their efficacy or lead to life threatening responses due to innate immune response 
modulating impurities.[128], [129] Hence, in the case of therapeutic monoclonal antibodies, the 
presence of masked endotoxin could lead to inadvertent side reactions. Consequently, 
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continuous improvement of endotoxin detection methods is essential to maintain and improve 
patient safety. 
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4.5 Key findings 
Endotoxin testing is mandatory in quality control of parenteral drug products. Low 
recovery of known endotoxin contents has led to the presented work and resulted in the 
following findings:    
 The occurrence of the Low Endotoxin Recovery (LER) is time and temperature dependent. 
LER can be detected after minutes to hours and days of sample incubation depending on 
the experimental setup. To thoroughly identify if a sample (e.g. drug product) is affected 
by LER, incubation temperature and periods have to reflect handling and storage 
procedures of tested samples.  
 LER is caused by endotoxin masking. Endotoxin detection assays have been proven 
functional, but detectability of endotoxin is limited due to alteration of its supramolecular 
aggregation state, which in turn can be manipulated by the sample matrix. It is supposed 
that endotoxin is monomerized in its masked state. 
 Common formulation components of biopharmaceutical drug products like surfactants 
and buffer systems as well as proteins can lead to LER. However, only the simultaneously 
presence of amphiphilic molecules and complex formation agents cause LER. The 
complex formation capability of a sample matrix strongly determines the reaction rate.  
 Endotoxin masking is associated with a two-step reaction mechanism. In a first step, 
endotoxin aggregates are permeabilized by destabilization of salt bridges between 
endotoxin molecules. In a second step, amphiphilic molecules like surfactants intercalate 
between endotoxin molecules and result in masking of endotoxin.  
 Endotoxins from different sources possess different susceptibilities to endotoxin 
masking. Depending on the molecular structure of endotoxin, different stabilization 
mechanisms are used. Endotoxins with substantial contents of positively charged 
substituent’s (e.g. 4-amino-4-deoxyarabinose) are less susceptible to masking. 
 Demasking of endotoxin is possible. Endotoxin can be released from its masking complex 
and detected again using common detection methods. Sample treatments using 
dodecanol, calcium dicholoride, sodium dodecyl sulfate and bovine serum albumin have 
been shown to be very effective. It is most likely that endotoxin reaggregates and forms 
inverted aggregates. 
 Sample treatment for demasking is case related. Depending on the sample matrix, above 
described components and combination thereof as well as concentrations have to be 
adapted case by case. Co-surfactants like long chain alkyl alcohols have been identified 
as key components and are necessary in all cases.  
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